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Abstract 
Adjuvants are commonly included in vaccines and have been invaluable in making them safer and 
more robust. Despite their prolific use, adjuvant mechanisms of action remain poorly understood. Many 
receptor-mediated mechanisms have been proposed for adjuvants, and many likely contribute to their 
mechanisms of action, but several adjuvants also interact with the plasma membrane. Although few have 
considered how lipid-mediated interactions contribute to adjuvanticity, previous studies suggested aluminum-
based adjuvants (ABAs) have high affinity for sphingomyelin and cholesterol, which allowed them to activate 
dendritic cells exclusively through lipid sorting. This dissertation sought to understand how lipid interactions 
contribute to the immunostimulatory properties of adjuvants. The membrane interaction of Alhydrogel (AH) 
and Adju-Phos (AP) was initially investigated in a simple lipid monolayer representative of the outer leaflet of 
the plasma membrane. AH and AP interacted with the model monolayer and promoted lipid clustering, 
although the physiochemical properties of each adjuvant caused them to interact differently. In a more 
complex lipid system containing sphingomyelin and cholesterol, the lipid interaction behavior was consistent 
and revealed AH and AP stabilized sphingomyelin- and cholesterol-rich lipid domains even in the presence of 
an antigen. Lipid raft clustering observed in dendritic cells exposed to ABAs in vitro was reminiscent of 
domain clustering observed in the monolayer and corresponded to conditions which enhanced cell activation, 
suggesting membrane interactions and lipid sorting could indeed contribute to ABA mechanisms of action. 
Lipid-interactions were also considered while designing an adjuvant-based antigen-specific immunotherapy 
(ASIT). An MF59-analog (MF59a) made in our lab was selected to co-deliver ovalbumin and dexamethasone 
based on its ability to solubilize dexamethasone, extend its release, and enhance its membrane permeability 
and internalization. The combination of MF59a, ovalbumin, and dexamethasone inhibited several pro-
inflammatory cytokines in dendritic cells and ovalbumin-educated splenocytes, and proved emulsion adjuvants 
could provide an ideal vehicle to create targeted, tolerizing ASITs. Therefore, lipid interactions can provide 
valuable insight while selecting the physiochemical properties of an adjuvant for pro- and anti-inflammatory 
applications. Our results provide compelling evidence that lipid interactions participate in adjuvant 
mechanisms of action, and should be considered when developing novel vaccines and adjuvants.  
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Vaccines have been an essential part of reducing the severity, if not eliminating many infectious 
diseases. The availability, safety, and efficacy of many of these vaccines can be attributed in many ways 
to the use of adjuvants. Adjuvants are used to enhance and shape an antigen-specific immune response. 
The ability to isolate the immunogenic portion of a pathogen into a highly-purified protein antigen has 
made vaccines safer; however, administering this purified antigen alone typically does not create any 
robust immune protection without multiple immunizations. Therefore, a purified antigen may be delivered 
in combination with an adjuvant to elicit stronger immune protection with far less antigen [1].  
Many materials have been investigated for use as adjuvants, but until recently the only FDA-
approved adjuvants were aluminum-based adjuvants (ABAs). Squalene-based oil-in-water emulsions 
AS03 and MF59 were approved for use in flu vaccines in the US in 2013 and 2015, respectively, nearly 
twenty years after the approval of MF59 in Europe. Interestingly, despite their long history of use, 
particularly for the ABAs, the precise mechanisms of action for either of these adjuvants are poorly 
understood. In general, these adjuvants are observed to 1) promote antigen uptake by antigen-presenting 
cells (APCs), particularly dendritic cells and macrophages, 2) create damage or inflammation, and 3) 
recruit cells to the injection site [2]. 
A variety of factors undoubtedly play a role in each adjuvant’s mechanisms of action; however, 
investigating the dynamic interactions between the plasma membrane and an adjuvant, like those 
summarized in Table 1, could provide insight. Here, we delve into how the characteristics of approved, 
particulate adjuvants, such as ABAs and emulsions may dictate their stabilizing or disruptive effect on the 
cell membrane, and how this interaction shapes the immune response.  
1. The cell membrane and immunity 
The plasma membrane is an astoundingly heterogeneous and complex surface which mediates 
cell function and communication. The mammalian plasma membrane is primarily composed of 
glycerophospholipids, and has the highest content of sphingolipids and sterols, namely cholesterol, 
compared to other cellular membranes (Fig 1) [3]. Glycerophospholipids are a diverse family of lipids, 
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and are the major component of cell membranes. Cells synthesize phospholipids with a variety of 
chemical moieties linked to their common phosphate base to produce anionic headgroups, such as 
phosphatidylinositol (PI), phosphatidylserine (PS), and phosphatidylglycerol (PG), or zwitterionic 
headgroups, such as phosphatidylcholine (PC) and phosphatidylethanolamine (PE). Additionally, lipids 
can differ in each of their acyl chains, which can also vary in length, saturation, and linkage to the 
glycerol backbone [3, 4]. Much like phospholipids, many sphingolipids can be produced by adding 
various side chains and head groups to ceramide, but the main sphingolipids are sphingomyelin and 
glycosphingolipid with saturated fatty acid chains [3]. Certain phospholipids are enriched in either the 
inner or outer leaflet of the bilayer. Anionic lipids and PE localize on the inner leaflet, while PC and 
sphingomyelin are mostly found in the outer leaflet [3, 5].  Furthermore, phospholipids are distributed 
differently within the leaflet. Differences in lipid charge and fatty acid chain structure promotes different 
affinities and packing between lipids, resulting in the formation of microdomains within the membrane 
and heterogeneity in the lateral distribution of lipids [3, 5].  For instance, as a small, rigid, and 
hydrophobic lipid, cholesterol preferentially interdigitates within hydrophobic, rigid unsaturated fatty acid 
chains and regulates membrane structure and fluidity. Although cholesterol associates with phospholipids, 
it has high affinity for the complementary structure of sphingomyelin. The preferential mixing of 
cholesterol and sphingomyelin produces tight, highly ordered domains and forms the basis for lipid rafts 
[3, 5, 6]. The raft-hypothesis, originally presented by Simon and co-workers, proposes that to coordinate 
different cellular functions, membrane lipids laterally phase separate into highly organized nanostructures 
or domains [7]. While the raft hypothesis is still contentious, recent technological advances uphold the 
hypothesis by providing compelling evidence of membrane heterogeneity and preferential self-association 
in living cells [3, 8]. 
Lipid rafts are ordered lipid domains rich in sphingolipids, cholesterol, and proteins. Rafts are 4-
200 nm in diameter, typically composed of tightly packed saturated lipids, and are laterally mobile in the 
mostly unsaturated, fluid-disordered sea of membrane lipid [9-11]. Lipid rafts appear to be critical in 
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spatially organizing molecules and in the initiation and maintenance of signaling. Signaling encompasses 
a complex series of events and necessitates the organization of proteins, lipids, and a number of chemical 
processes. Evidence suggests lipid rafts can significantly reduce the mobility of associated proteins, and 
thus can provide a platform to sort and facilitate receptor-mediated signaling at the appropriate time and 
place [3, 11, 12]. In immune cells, lipid rafts maintain separation of activating signaling proteins in resting 
cells. While some important immune-signaling proteins reside in lipid rafts, such as CD14, CD4/CD8, 
Src-family kinases, and the linker for activation in T cells (LAT), they do not exert their effect until 
additional proteins partition into rafts upon ligand binding [3, 12, 13].  For instance, TLRs typically exist 
outside lipid rafts, but after activation by LPS or lipoteichoic acid, TLR4 and TLR2, respectively, 
translocate into lipid rafts [11, 14]. Similarly, both the T-cell receptor (TCR) and B-cell receptor (BCR) 
translocate into lipid rafts following conformational changes that occur after binding antigen  [3, 11, 15, 
16]. Additionally, MHC-II has been shown to be constitutively lipid raft-associated in many antigen 
presenting cells such as B cells, monocytes, and dendritic cells [9]. Upon ligand binding, raft-associated 
proteins with help from the actin cytoskeleton are observed to coalesce into larger domains to form 
immunological synapses. The aggregation of lipid rafts organizes signaling and adhesion molecules at the 
center and periphery of the synapse, respectively, to enable phosphorylation and signaling events 
resulting in robust immune activation [3, 6, 15, 17, 18]. Once signaling is complete, or in the absence of 
sufficient stimulation, the lipid rafts diffuse away.  
In contrast to signaling activated by highly ordered lipid rafts, disrupted and damaged membranes 
also result in immune responses. The immune response to membrane changes following cell death can 
differ greatly depending on whether the cell is undergoing apoptotic or necrotic cell death. Apoptosis is a 
healthy, programed form of cell death involving membrane blebbing, cell shrinkage, and condensation 
and fragmentation of nuclear contents [19, 20]. In homeostatic cell death, apoptotic cells release 
chemoattractants, such as ATP, to recruit antigen presenting cells, and mark themselves for phagocytosis 
by exposing typically-intracellular lipids, like phosphatidylserine to the extracellular space [19, 21]. 
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Apoptotic cells are typically cleared by phagocytes before releasing their intracellular contents and 
promote the secretion of immunosuppressive cytokines, and thus can be silently removed without 
initiating an immune response [20, 21]. Conversely, cells undergo necrosis after membrane injury or 
infection. Necrosis is associated with the loss of membrane integrity and the release of danger associated 
molecular patterns (DAMPs) from the intracellular contents. DAMPs, such as monosodium urate 
precipitated from uric acid and host DNA, are recognized by pattern recognition receptors on antigen 
presenting cells and stimulate the inflammasome and subsequently adaptive immune responses [21, 22]. 
Literature reveals a multitude of pathways that can initiate cell death, therefore both the trigger and the 
means by which cell death is communicated can have a significant impact on the resultant immune 
response [21]. Thus, lipid organization and disruption can play a large role in potentiating immune 
responses, and understanding how adjuvants may interact with membrane lipids and their associated 
signaling pathways may improve our understanding of their mechanisms of action. 
2. Membrane interactions of adjuvants 
2.1 Aluminum-based adjuvants 
Despite their abundance, the mechanisms of action of aluminum-based adjuvants (ABAs) remain 
elusive. There are many forms of ABAs including alum, referring to hydrated potassium aluminum 
sulfate, aluminum oxyhydroxide (Alhydrogel), aluminum hydroxyphosphate (Adju-Phos), and the 
experimentally used combination of magnesium hydroxide and aluminum hydroxycarbonate (Imject) (Fig 
3). Particularly in the case of Imject, the differences in composition could contribute to the disparities in 
reported mechanisms of action, and thus mechanisms reviewed here will be limited to the clinically 
relevant Alhydrogel and Adju-Phos [23, 24]. Particulate aluminum salts possess a high charge density and 
typically electrostatically adsorb antigens to their surface. However, aluminum adjuvants with surface 
hydroxyls are also capable of forming covalent bonds with antigens that possess phosphate groups. 
Aluminum has a higher affinity for phosphate groups than hydroxyl groups, therefore phosphate groups 
can displace surface hydroxyls to create an inner-sphere surface complex with aluminum and effectively 
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create a covalent bond [25, 26]. Upon injection and exposure to the interstitial fluid, antigens associated to 
ABAs via weaker electrostatic interactions tend to release faster, whereas antigens that are bound to the 
ABA may not release at all depending on their degree of phosphorylation and ligand exchange [25, 27, 
28]. 
Early hypotheses regarding ABA mechanisms of action proposed formation of a depot at the 
injection site which slowly released antigen, but the necessity of depot formation has since been 
contradicted given the strong antigen-specific antibody response that occurs even after immediately 
excising the injection site  [29].  ABAs have consistently been observed to promote immune cell 
recruitment to the injection site, antigen uptake, and migration to the draining lymph nodes [30, 31]. The 
particulate nature of ABAs is credited with enhancing antigen uptake, as aluminum-adsorbed antigen can 
be several hundred nanometers or in the micrometer range, allowing them to more efficiently be taken up 
by antigen presenting cells like dendritic cells (DCs) and macrophages [32]. However, the call to take up 
antigen is suspected to be linked to ABA-induced inflammation. In fact, inflammation may be a 
significant part of ABA’s adjuvanticity.  
ABAs can induce local irritation in muscle tissue, which produces pro-inflammatory cytokines, 
chemokines, and radical oxygen species resulting in cell damage and, most commonly, necrosis (Fig 2) 
[22, 33, 34]. Release of extracellular contents after necrosis produces danger-associated molecular patterns 
(DAMPs).  After ABA administration, DAMPs such as uric acid, ATP, and host DNA are commonly 
observed [35] and can activate the NLRP3 inflammasome. NLRP3 activation (and its necessity for ABA 
adjuvanticity) has been detailed and debated extensively elsewhere [36].  Although the initiation of the 
inflammasome pathway and its involvement in ABA adjuvanticity remains controversial, the disruption 
of lipid membranes to release cytoplasmic or phagosomal contents appears to be important in its 
activation. Seminal papers on NLRP3’s role in ABA’s adjuvanticity propose the adjuvants may indirectly 
activate NLRP3 via release of MSU and ATP, or may directly activate it by disrupting the phagolysosome 
after uptake, subsequently releasing cathepsin B into the cytoplasm [22-24, 37, 38]. Although not 
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frequently considered, the nanoscale interaction between aluminum adjuvants and membrane lipids could 
provide insight to this and other membrane-associated mechanisms of action.  
Inflammasome activation necessitates phagocytosis of the ABA vaccine particle, but it is possible 
ABAs exert their adjuvanticity without entering an antigen presenting cell (APC). Adjuvants are generally 
accepted to enhance particle phagocytosis by APCs, indeed ABA uptake has been observed in several 
macrophage and dendritic cell cultures [31, 39-41], but in a publication by Flach and Ng et. al., aluminum-
based adjuvants reportedly potentiated immune responses via association with the dendritic cell 
membrane. Experiments using pronase-treated DC2.4 cells and an aluminum adjuvant-modified AFM tip 
revealed ABAs did not have a receptor, but had high affinity for sphingomyelin and cholesterol, the major 
components of lipid rafts, which mediated its strong interaction with the membrane. Lipid engagement 
induced lipid sorting and signaling typically associated with phagocytosis, but contrary to previous 
observations, the adjuvant particle was not phagocytosed. Instead, antigen was delivered by endocytic 
uptake and was still processed and presented on MHC II. Lipid sorting induced phagocytic-signaling by 
the ITAM-Syk-PI3K pathway, and not the NLRP3 inflammasome, and activated DCs that engaged and 
activated CD4+ T cells [42, 43]. Despite their report that DCs do not phagocytose ABAs, it is worthwhile 
to note the authors acquiesced both the detection of intracellular aluminum, and the abortive phagocytosis 
observed may be unique to their experimental conditions [42]. Additionally, the lack of phagocytosis in 
the immortalized DC cell line was based on Imject or cesium aluminum crystals, which have drastically 
different composition and crystal morphology compared to clinically-relevant ABAs (Fig 3). Though 
experiments which used both Imject or cesium aluminum and an aluminum hydroxide adjuvant showed 
comparable results.  
The ability of aluminum adjuvants to sort membrane lipids, particularly lipid-raft relevant lipids, 
and initiate signaling offers additional insight into mechanisms. Studies in Langmuir troughs using 
synthetic zwitterionic lipid monolayers, typically considered to have low ABA-affinity [42, 44], revealed 
surface activity of both Alhydrogel and Adju-Phos. Each adjuvant was observed to interact with the 
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DPPC:DOPC monolayer and promote the formation of liquid-ordered (Lo) domains, although they 
appeared to do so differently. Whereas the negatively-charged Adju-Phos facilitated the organization of 
large, condensed domains without compromising the integrity of the monolayer, positively-charged 
Alhydrogel promoted domain-clustering to a point, after which its proposed insertion in the monolayer 
interrupted lipid packing leading to the monolayer’s collapse [44]. Furthermore, in lipid systems 
composed of an equimolar ratio of POPC:POPE:Sphingomyelin:Cholesterol, compared to the lipid alone 
both Alhydrogel and Adju-Phos stabilized the presence of condensed Lo domains similar in composition 
to lipid rafts, even in the presence of antigen (Antúnez et. al. manuscript in preparation). Basal 
phosphorylation of raft-resident proteins with immunoreceptor tyrosine-based activation motifs (ITAM) is 
observed in DCs [45]. Therefore ABA-induced clustering of raft-associated phosphorylated ITAMs or 
resident intracellular proteins could propagate signaling cascades leading to activation. Thus, lipid-
sorting-induced signaling could indeed be part of the mechanism of action of aluminum adjuvants. 
Aluminum adjuvants most likely interact with membrane lipids predominantly via ligand 
exchange and electrostatic interactions. As detailed earlier, phospholipids are the major lipid component 
of the plasma membrane and possess phosphate moieties in their head groups [3]. The phosphate group 
may undergo ligand exchange with available hydroxyl groups on the surface of aluminum adjuvants and 
form a covalent bond [46]. In fact, novel adjuvant formulations have capitalized on the Alhydrogel-
phospholipid association to deliver poorly soluble TLR-ligands on ABAs by first encapsulating them in 
PC- or PG-based liposomes [47, 48]. Conceivably, the ABA-phospholipid bond is less productive in the 
cell membrane and could disrupt lipid packing or remove lipid from the membrane, causing the cell 
damage that has been observed with ABAs. Ligand exchange is possible even in the presence of repulsive 
charges [25]; however, complementary electrostatic interactions are the more common mode of ABA 
adsorption and a likely mechanism of lipid interaction. The association of charged particles with synthetic 
and natural lipid membranes and the ensuing changes in lipid packing have been well documented [49, 
50]. For instance, in single-component PC bilayer vesicles, negatively charged nanoparticles were 
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observed to interact with the N+ terminus of the headgroup and caused local gelling of otherwise fluid 
lipids by promoting an extended orientation of the zwitterionic head group, aligning the head group with 
the lipid tails and allowing them to pack more closely (Fig 4). Conversely, positively charged 
nanoparticles preferentially interacted with the phosphate group and oriented the headgroup at a greater 
angle from the lipid tails, providing greater space between the lipids and locally fluidizing otherwise 
gelled membranes [51]. Interestingly, cationic particles are frequently observed to form holes in both 
synthetic and cellular lipid membranes [49]. Likewise, charged ABAs have been observed to alter 
membrane packing, and has been offered as part of its mechanism of action.  
Aluminum adjuvants are not the only particle structures capable of promoting non-receptor-
meditated inflammation and activation. MSU crystals were also discovered to have strong affinity for 
cholesterol, allowing them to strongly interact with DC membranes resulting in their activation. MSU-
cholesterol binding also induced clustering of lipid rafts and ITAM-receptors resulting in the same Syk 
and PI3K signaling observed in the aluminum studies. Contrary to some reports on aluminum adjuvants 
discussed above [42], MSU particles were successfully phagocytosed. In the same study, latex beads were 
also found to similarly potentiate binding and activation of DCs, but basic calcium phosphate and 
allopurinol did not have membrane interaction, consistent with reports that these crystals do not activate 
DCs [45]. These data would suggest selective, particulate-initiated interactions may be sufficient to 
engage innate immune pathways or transmit activating signals across the membrane. Therefore, the nature 
of a particle’s interaction with membrane lipids and the resulting lipid sorting or damage could be a 
valuable consideration in selecting adjuvant surface properties and tuning immune responses.  
2.2 Emulsions 
Emulsions also have a long history as adjuvants, and their hydrophobic properties promote 
nonspecific interactions with lipid membranes. Among the earliest and most-used of these emulsions are 
Freund’s adjuvants. Freund’s adjuvants are water-in-oil adjuvants composed of non-metabolizable 
mineral oil and mannide monooleate surfactant. Alone these components are referred to as Incomplete 
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Freund’s Adjuvant, and become Complete Freund’s Adjuvant with the addition of mycobacteria. The 
viscous adjuvant is thought to create strong antibody responses by forming a depot at the injection site, 
protecting and slowly releasing the antigen while stimulating local innate immune responses [52]. 
Although later iterations of Freund’s adjuvants are more tolerable, the emulsion was determined to be 
unacceptable for use in humans due to severe reactions at the injection site such as abscesses, granulomas, 
and ulcerative necrosis [52, 53]. IFA reactivity was partially attributed to the heterogeneous chain lengths 
of the hydrocarbons that make up mineral oil, as well as mannide monooleate. Mannide monooleate can 
produce toxic fatty acids, and shorter chain lengths (<C14) present in the mineral oil are associated with 
injection-site reactivity and have detergent-like effects which can disrupt the cell membrane, resulting in 
cell lysis [33, 54, 55]. Although precluded from use in humans, Freund’s adjuvants continue to be used in 
veterinary vaccines [56]. 
Likewise, saponin-based adjuvants are common in veterinary vaccines and have known 
membrane-disrupting properties. Saponins are isolated from a variety of natural sources, and as such they 
are a heterogeneous family which produces a range of immunostimulatory effects, but the most common 
fraction is isolated from the bark of the Quillaja saponaria tree, QS21 [56-60]. Saponins are proposed to 
exert their adjuvant effect through the induction of cytokines [56], but they are also capable of forming 
irreparable gaps in the cell membrane via interaction with cholesterol [56, 58]. Saponins may interact with 
the polar heads of phospholipids or the hydroxyl groups of cholesterol to create insoluble aggregates 
which permeabilize the membrane and may allow endocytosis of the antigen or cell lysis [33, 56, 58]. QS-
21, although less toxic than other saponins, still has hemolytic activity which is attributed to its fatty acid 
moiety [57]. To mitigate its reactivity but maintain its strong action as an adjuvant, QS21 and other 
saponin fractions have been formulated in liposomes or emulsions (i.e. AS01, AS02, ISCOMs) which 
typically include phospholipids or cholesterol to intercept its membrane activity [56, 60, 61]. Immune 
stimulating complexes (ISCOMs) have also been observed to destabilize the endosomal membrane [62]. 
Progress has been made in making both saponin-based and Freund’s adjuvants more tolerable, allowing 
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their use in veterinary vaccines; however, successful emulsion adjuvants used in humans thus far have 
been based on metabolizable oils. 
2.3 MF59  
MF59 is an oil-in-water emulsion based on metabolizable squalene. The emulsion is composed of 
squalene droplets 150-200 nm in diameter stabilized by the non-ionic surfactants Span 85 and Polysorbate 
80 suspended in citrate buffer [63]. Although approved for use in Europe since 1998, it only recently 
gained FDA approval in 2015 for use in the seasonal flu vaccine, Fluad. Unlike the ABAs, MF59 does not 
associate with the antigen, which is typically present in the aqueous phase. The mechanism of action of 
MF59 is also poorly understood, but it appears to begin its adjuvant effect in the local muscle tissue 
where the release of chemokines and cytokines is initiated. Waves of immune cells are attracted to the 
injection site and add to the “immunocompetent environment” which promotes antigen uptake, migration 
of antigen-loaded antigen presenting cells (APCs) to the draining lymph nodes, differentiation of 
monocytes to DCs, and strong adaptive immune responses [63]. 
MF59 may be able to achieve this environment by easily interacting with many cell types. The 
adjuvant was observed to enhance all forms of endocytosis, and it was visually confirmed to enter both 
APCs, like monocytes, macrophages, and DCs, and muscle tissue cells like fibroblasts and myotubes [64, 
65]. In fact, MF59 interaction with ATP-rich muscle fibers appears to be an important part of its 
mechanism of action. The release of ATP at the injection site is critical to MF59’s adjuvanticity as 
consumption of MF59-induced ATP using apyrase abrogated its ability to recruit cells and create robust 
antibody titers [65, 66]. Interestingly, despite a study showing no individual component of MF59 could 
produce the full adjuvant effect of the whole formulation, the surfactants present in the MF59 formulation 
were necessary for ATP release [66, 67].  
Surfactants by nature are typically amphiphilic and many surfactants easily incorporate into 
membranes. Although Span 85 and Polysorbate 80 may not be solely responsible for the adjuvant effect 
of MF59, their ability to interact with the cell membrane can still initiate some immune response [66]. In 
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cases of cell death, surfactants can permeabilize the cell membrane leading to necrosis, apoptosis, or cell 
cycle arrest in a surfactant- and concentration-dependent manner [19]. Evidence of MF59-induced 
necrosis in macrophages has been observed in vitro [31].  In vivo, apoptotic macrophages were found to 
activate DCs in the lymph node with the help from the pro-inflammatory milieu [68]. Interestingly, 
although MF59 uptake leads to ATP and DAMP release, MF59 was found to exert its adjuvanticity in a 
NLRP3 inflammasome-independent manner [66, 69, 70]. In fact, MF59 reportedly does not disrupt the 
lysosome, but rather acidifies and stabilizes it [65]. 
Even if surfactant-interaction does not lead to cell death, uptake and metabolism of the 
surfactants and squalene can increase accumulation of neutral lipids and inflammation [65]. Significant 
MF59 uptake was observed in the aforementioned APCs and muscle cells, and high- and low-density 
lipid inclusions were observed, indicative of metabolized and engulfed MF59, respectively (Fig 5) [31, 
65]. Squalene is a precursor of cholesterol, and while it did not increase total cholesterol levels in cells, it 
did increase the levels of cholesterol metabolites. Likewise, oleic acid metabolites from Polysorbate 80 
likely contributed to the increase in triglycerides. Notably, a “massive” accumulation of diacylglycerols 
(DAGs) was observed in MF59-treated cells, which was also speculated to be a result of surfactant 
metabolites [65]. Accumulation of DAGs is particularly interesting as they are important signaling lipids 
in the immunological synapse [3, 65].  Overall, the buildup of neutral lipids including squalene have been 
shown to have pro-inflammatory and pro-apoptotic properties and may be able to activate innate signaling 
pathways [65].  
While the exact mechanism of lipid interaction requires more investigation, the surfactant content 
and hydrophobic nature of MF59 facilitates its interaction with the plasma membrane. Permeabilization of 
the membrane by surfactants could expose phosphatidylserine in apoptotic cells or release DAMPs in 
necrotic cells, all of which would recruit and promote uptake by APCs. Alternatively, ATP release is also 
a product of phagocytosis, and emulsion metabolism within the cell has been proven to initiate a slew of 
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immune activating signals, which could complement any danger-associated signaling. Therefore, the role 
of lipids in the mechanism of MF59 could be multifaceted. 
3. Concluding Remarks 
The cell membrane is an exceedingly complex surface we are only beginning to appreciate as our 
ability to study it improves. Lipids play a major role in initiating and propagating immune responses by 
providing an organizing platform for signaling molecules, or by serving as signaling molecules 
themselves in the immunological synapse or in cell damage and death. Receptor-mediated pathways are 
undeniably instrumental in potentiating immunity; however, non-specific membrane interactions (i.e. 
charge, hydrophobic interactions, specific lipid affinity) may point to the most fundamental means by 
which cells can detect and react to their surroundings. 
Both aluminum-based and emulsion adjuvants are capable of interacting with lipids in the cell 
membrane, and there is strong evidence to support this interaction could contribute to their mechanisms of 
action. Disparities in the observed mechanisms of action reported in the literature may even be attributed 
to membrane interactions. For instance, while one aluminum adjuvant may promote local lipid domain 
formation, organization, and activation via electrostatic interactions, a different concentration or 
aluminum adjuvant may lead to greater binding of phosphate groups in phospholipids leading to 
membrane damage and a separate immune signaling pathway. In the case of emulsions, the concentration 
and selection of surfactants can influence whether the droplets are endocytosed and processed or induce 
cell lysis. Additionally, metabolism of fatty acid chains in emulsions can lead to the formation of new 
lipid species which can both up- and down- regulate immune activation [3].  Interestingly, non-specific 
hydrophobic interactions with membrane receptors could also have some role in how emulsions work. 
Although MF59, IFA, and saponin emulsions have all been shown to function independent of TLR 
activation, all these adjuvants show overlap with TLR gene products or signaling pathways [53, 60, 62, 69, 
71]. Both TLR2 and TLR4 are reportedly promiscuous receptors and can be activated by several 
hydrophobic structures [72], highlighting that non-specific interactions not only with the membrane, but 
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with membrane bound receptors may contribute to adjuvant mechanisms.  Therefore, although the cell 
membrane is often overlooked, lipid-adjuvant interactions warrant greater attention. The lessons learned 
with current adjuvants can be used to our advantage to synthesize and formulate novel adjuvants which 
improve our ability to tune desired immune responses. 
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Table 1. Examples of adjuvants with known membrane activity 
Adjuvant Class Examples Membrane 
interaction 
Immune-activating effects Ref 
Aluminum 
Salts 
Particulate Alhydrogel, 
Adju-Phos 
Charge 
interactions, 
Phospholipid 
ligand exchange, 
Affinity for 
sphingomyelin & 
cholesterol  
Membrane damage/necrosis, 
ROS formation by surface 
hydroxyls,  
Lipid sorting and clustering 
(particularly lipid rafts) 
[34] 
[42, 
73] 
[44] 
Emulsions Oil-in-
water 
emulsion 
MF59, AS03 Hydrophobic 
interactions 
Necrosis following membrane 
permeabilization/detergent 
effects of surfactants/short 
chain fatty acids,  
Accumulation of neutral lipids,  
Uptake by non-phagocytic cells 
[66]  
[67]  
[19]  
[31] 
Water-in-
oil 
emulsion 
Freund’s 
Adjuvants 
Hydrophobic 
Interactions 
[33] 
[54] 
[55] 
Saponins Liposomes, 
Emulsions 
AS01, AS02, 
ISCOM/ 
ISCOMATRIX 
Affinity for 
cholesterol 
Aggregates with cholesterol and 
forms holes in plasma 
membrane  
[57]  
[74] 
[56] 
[61] 
[60] 
Monosodium 
Urate 
Particulate, 
Crystal 
 Affinity for 
cholesterol 
Lipid raft clustering [45] 
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Figure 1. Diversity in lipid structures. Cells can generate a wide array of glycerophospholipid and 
sphingolipid species by linking different chemical moieties to their common phosphate base at the sn-3 
position. Fatty acid side chains of variable length and saturation add further lipid heterogeneity. Common 
molecular-shape volumes occupied by each lipid are shown, as well the lipid polymorphisms produced by 
their assembly. The shape volumes commonly associated with sterols and sphingolipids are inverted cone 
and cone, respectively. SM, sphingomyelin; Chol, cholesterol. Figure adapted from [3], [5], and [75]  
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Figure 2. Evidence of membrane damage after exposure to aluminum adjuvants. Loss of membrane 
integrity has been observed in (a) dendritic cells [42], (b) THP-1-derived macrophages exposed to 50 
g/mL (middle) or 200 g/mL AlO(OH) [39], and (c) bone-marrow derived macrophages cultured with 
aluminum adjuvants [31]. (d) Extracellular accumulation of DNA was also observed at the injection site 
after intramuscular injection with aluminum hydroxide adjuvant [35]. 
 
 
 
Figure 3. TEM images showing the structure of (a) Alhydrogel, (b) Adju-Phos, (c) Imject, and (d) cesium 
aluminum adjuvants. (a) and (b) adapted from [76], (c) and (d) from [42] 
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Figure 4. Charged particles reorient phospholipid heads and alter lipid packing. (a) Positively charged 
nanoparticles promote a more extended orientation of the PC head, preventing lipids from packing as 
tightly, creating a more fluid membrane. (b) Negatively charged particles prefer to interact with the 
positive terminus of the PC head, lengthening the phospholipid and allowing the lipids to pack more 
densely, creating a more solid or gelled membrane. Figure adapted from [51] 
 
 
 
 
 
 
 
 
 
 
Figure 5. MF59 uptake and metabolism in various cells. (a) An untreated bone marrow-derived 
macrophage (BMM). (b) Dark, high-electron dense bodies indicative of lipid metabolism and brighter, 
low-electron dense bodies indicative of engulfed MF59 are observed (i) in single BMMs and (ii) in the 
lymph nodes of mice. Images adapted from [31]. (c) Neutral lipid accumulation in macrophages, 
monocytes, and myotubes after incubation with MF59. Images adapted from [31, 65]. 
 
 
 
 
(a) (c) 
(b) 
(i) (ii) 
Myotube Monocyte Macrophage 
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1. Introduction 
Vaccines are a staple of modern, preventative medicine, and have become increasingly safer and 
more potent due in large part to the use of highly purified antigens and adjuvants. Adjuvants are regularly 
added to vaccine formulations to bolster the immune response to what are typically insufficiently reactive 
isolated antigens [1, 2]. The most common adjuvants, aluminum salts, have been in vaccines since 1926; 
yet, fairly little is known about their precise mechanism of action [3, 4]. The prevailing mechanism of 
action suggests aluminum-based adjuvant particles initiate “danger signals” or enhance receptor-mediated 
antigen uptake by antigen presenting cells, particularly dendritic cells (DCs), but Shi and co-workers 
recently offered a paradigm shift in aluminum interaction mechanisms [2-5]. Using DCs, Flach and Ng et 
al. showed the adjuvanticity of aluminum relied neither on inflammasome activation, receptors for the 
antigen, nor any receptor for aluminum [5, 6]. Instead, the authors proposed a novel mechanism after 
observing aluminum adjuvants can directly engage and reorganize lipids that form the major components 
of lipid rafts in membranes [1, 5, 7, 8]. However, details of colloidal, aluminum adjuvant-induced lipid 
organization remain unexplored and provide the main motivation for this study.   
Elucidating the mechanisms of adjuvant-induced lipid reorganization in cellular membranes 
requires understanding the interactions between the adjuvant and individual phospholipids.  In this study, 
we wished to elucidate if all major components of lipid rafts (namely sphingomyelin and cholesterol) 
were also essential for adjuvant-lipid interactions in model membranes.  Therefore, in this study, we 
focused on adjuvant induced lipid clustering in zwitterionic phospholipid monolayers composed of 
saturated dipalmitoyl-phosphatidylcholine (DPPC) and unsaturated dioleoyl-phosphatidylcholine 
(DOPC). The choice of saturated and unsaturated PC lipids mimic the biphasic nature, as well as the 
major phospholipid headgroup of the outer leaflet of cell membranes. We compared the lipid domain 
clustering and reorganization induced by two common aluminum adjuvants, Alhydrogel and Adju-Phos. 
Alhydrogel (AH) contains crystalline, needle-like nanoparticles that form loose aggregates of 
approximately 15 μm, while Adju-Phos (AP) has an amorphous, plate-like structure with particles 
approximately 50 nm in diameter that form roughly 5 μm aggregates [3]. Furthermore, AH and AP are 
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positively and negatively charged, respectively, at physiological pH [2, 9-11]. Using both surface pressure-
area isotherms and fluorescence imaging techniques, our results establish, for the first time, that colloidal, 
aluminum-based adjuvants are capable of reorganizing lipid ordered domains even in simple two-
component zwitterionic phospholipid mixtures. However, each adjuvant organizes and condenses the 
lipid domains differently, likely due to differences in charge and morphology.  
2. Materials and Methods 
2.1 Materials 
 Lipid solutions contained a 1:1 ratio by weight of 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine 
(DPPC) and 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC) (Avanti Polar Lipids, Alabaster, AL) 
suspended in high performance liquid chromatography grade chloroform (Fisher Scientific) to a total lipid 
concentration of 1 mg/mL. For imaging studies, the lipids were mixed with 1 wt% Texas Red -DHPE 
(Life Technologies, Carlsbad, CA). Alhydrogel 2% (AH) and Adju-Phos 2% (AP) were purchased from 
Sergeant Adjuvants (Clifton, NJ).  
2.2 Surface Pressure-Area Isotherms 
A Langmuir trough (KSV-NIMA-Biolin Scientific, Linthicum Heights, MD) was used to measure the 
interaction of the adjuvants with the lipid monolayers. DPPC:DOPC in chloroform was spread dropwise 
with a Hamilton microsyringe (Hamilton, Reno, NV) to form a monolayer on the surface of an ultrapure-
distilled water subphase (18.2 MΩ/cm; Millipore, Billerica, MA) to a mean molecular area of 
approximately 90 Å2/molecule. Water was used in these experiments to avoid any effects of free ions in a 
buffer solution interacting with the monolayer or the adjuvants. The monolayer at the air-water interface 
was compressed symmetrically at 25 mm/min using two Teflon barriers, decreasing the trough surface 
area from 87 cm2 to 20 cm2. The resulting changes in the pressure of the phospholipid film were recorded 
by a Wilhelmy plate pressure sensor. A wet filter paper was used as the pressure sensor probe and was 
calibrated using a bare air-water interface.  
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In adjuvant experiments, each adjuvant stock was mixed into the subphase prior to spreading the 
monolayer. A range of concentrations of adjuvants were initially tested, but surface pressure vs area 
isotherms of DPPC:DOPC films showed that changing the adjuvant concentration over several orders of 
magnitude minimally changed the compression isotherm (Figure S3). The working concentration for all 
studies was selected to be 0.03 mg Al/mL and remained well-suspended throughout the subphase during 
each experiment; no precipitated adjuvant particles were observed within the trough (Figure S4).  
The methods used to isolate and test the adjuvant suspension buffer and to create the aluminum ion 
solution are detailed in the supplementary information (Figure S1 and S2, respectively). Surface pressure 
vs. area isotherms were repeated at least three times for each experimental condition and the replicates of 
the surface pressure at each mean molecular area were averaged. GraphPad Prism was used to calculate 
and plot the averages and standard error of the mean (GraphPad, San Diego, CA).  
2.3 Monolayer Compressibility Modulus 
Monolayer compressibility modulus defines a Langmuir monolayer’s ability to store the energy provided 
by an applied force, or the monolayer’s ability to resist strain.  Mathematically, the bulk compressibility 
modulus, , is defined as  
A
A


  
High compressibility modulus indicates rigid monolayers due to limited motion of the highly ordered 
lipid molecules. Similarly lower values of the compressibility modulus are associated with fluid films.  
Because is a derivative of the Gibbs free energy, G, a discontinuity in the slope of the compressibility 
modulus indicates a first order phase transition and appears as a dip in the profile. To more accurately 
identify aluminum adjuvant-induced changes in the mechanical properties of the monolayer, including 
phase transitions, the compressibility modulus was calculated from the surface pressure vs mean 
molecular area isotherms with the built-in differentiation tool available in Origin 8.6 (OriginLab, 
Northampton, MA).  The raw data was smoothened by applying a five-point Fourier filter, also available 
in Origin.  
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2.4 Fluorescence Microscopy 
Fluorescence microscopy was used to monitor changes in the morphology of the lipid domains in the 
presence of the aluminum adjuvants. The Langmuir trough was placed under a custom-modified Nikon 
Eclipse LV100 fluorescence microscope with an extra-long working distance lens and tube collimators 
that allow simultaneous imaging of the phospholipid film during monolayer compression.  Images of the 
lipid monolayers were captured throughout the compression cycle using an Andor Luca S camera and 
Solis software (Belfast, Ireland).  The morphology of the lipid films is visible in fluorescence imaging 
due to selective segregation of the bulky Texas Red-DHPE dye molecules into fluid lipid phases.  
2.5 Image Analysis 
The area of each condensed lipid domain was analyzed using the “Analyze Particles” tool in ImageJ 
(National Institutes of Health, Bethesda, MD). Only particles with circularities between 0.1 and 1 were 
analyzed to exclude any background noise, and edges were excluded from analysis. The detected particle 
areas were organized and plotted as a normalized histogram in Origin 8.6. The number of bins, calculated 
as the square root of the number of measured domains, was used to assign bin widths. Adjuvant-induced 
condensation of lipid domains was based on the percent area of the image composed of dark domains and 
was calculated as the total area of condensed domains divided by the total area of the image. 
3. Results and Discussion 
Figure 1 presents representative surface pressure vs area compression isotherms of a 
DPPC:DOPC monolayer in the absence (solid line)  and presence of AH and AP in the subphase. 
DPPC:DOPC smoothly increased in surface pressure from zero  (referred to as the “lift-off” area) to 50 
mN m-1 as the trough barriers were compressed, decreasing the mean molecular area (MMA). Beyond the 
maximum surface pressure phospholipid molecules collapse into the bulk subphase, referred to as the 
collapse surface pressure. Corresponding to the changes in the surface pressure, the bulk modulus,  
steadily increased with decreasing MMA (Figure 1 b). The compressibility modulus reveals a phase 
transition observed as a dip to 35 mN m-1 near 60 Å2 molecule-1, indicating a reorganization of the 
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phospholipid film.  This change could be attributed to DOPC collapsing near 35 mN m-1, resulting in a 
DPPC-rich phospholipid film. The maximum compressibility reached by the film also corresponds to a 
rigid film.  
Addition of each of the adjuvants to the bulk subphase altered the characteristic DPPC:DOPC  
compression isotherm. Addition of AH (Figure 1 a) and AP (Figure 1 c) to the bulk subphase shifted the 
“lift off” area to higher MMAs compared to the DPPC:DOPC control, indicating an interaction with the 
phospholipids. The interaction of AH decreased the collapse surface pressure and lowered the maximum 
compressibility modulus. Since the compressibility modulus measures the rigidity of monomolecular 
films, the decrease suggests a disruption in the molecular packing and a reduction in the strength of the 
film. Conversely, the compressibility modulus of the monolayer was unaltered in the presence of AP, 
indicating the shift to higher MMAs resulted from enhanced packing density of the phospholipid 
molecules. 
The aluminum adjuvant-monolayer interactions were further explored with fluorescence 
microscopy. Representative images of the monolayer at physiologically relevant surface pressures are 
shown in Figure 2. The well-packed liquid condensed domains exclude the bulky fluorescent dye and 
appear dark against the bright liquid expanded regions. As has been previously reported in equivalent 
bilayer systems, DPPC:DOPC monolayers (Figure 2 a) contained small, fairly round, evenly-distributed 
domains which grew with increasing surface pressure [12-14]. Most of the domains ranged in size 
between 1.02.0 m2 at 20 mN m-1 and between 2.254.25 m2 at 30 mN m-1 (Figure 3 a). The domains 
were drastically condensed upon exposure to AH and AP (Figure 2 b,c), creating large, irregular-shaped 
domains. The adjuvants did not only increase the total image area composed of liquid condensed domains 
(Figure 3d), but also increased the median domain area and range of domain areas by more than an order 
of magnitude (Figure 3 b, c). Further, liquid condensed domains began appearing at approximately 12 mN 
m-1 for the DPPC:DOPC monolayer alone, 10 mN m-1 in the presence of AH, and 6 mN m-1 in the 
presence of AP. The early appearance and shape of the AP-induced domains and lack of change in the 
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compressibility modulus could indicate the AP particles provide nucleation points to promote lipid 
clustering and domain growth without disrupting the monolayer. 
McConnell and co-workers have shown that the size and morphology of liquid ordered domains 
is determined by the electrostatic repulsion between the molecular dipoles formed between the lipid 
headgroups at the air/water interface and the line tension between the ordered and disordered domains 
[15]. Further, some of us have shown that the entropy of mixing requires that the lipid domains 
demonstrate a domain size distribution [16, 17]. The increase in width and the loss of the Gaussian domain 
distribution in the presence of AH and AP are possibly due to changes in the electrostatic interactions of 
the lipid headgroups around the aluminum adjuvants.  Further, the incorporation of adjuvants into the 
lipid membrane could change the line tension between the lipid domain boundaries and cause the 
transition from circular to irregular shapes.  
Although aluminum-based adjuvants are particulate matter, similar counterion mediated 
clustering in lipid membranes is well established for lipid molecules involved in signaling. For example, 
divalent cations such as Ca2+ enhance condensation and organization of important anionic signaling lipids 
such as phosphatidylserine, phosphatidic acid, and PIP2 [18-21]. Electrostatic and phosphate-driven 
interactions between cell membranes and aluminum ions have also been proposed to explain well-known 
toxic effects of aluminum ions [22-25]. To prove that the observed lipid reorganization was induced by 
adjuvants and not free ions in solution, we exposed the DPPC:DOPC films to the adjuvant suspension 
buffer containing sodium (and other ions in trace amounts) and to a solution of free aluminum ions. The 
domains created in the presence of the suspension buffer and the DPPC:DOPC alone showed no 
morphological or quantitative difference (Figure S1). To obtain a solution containing free aluminum ions, 
aluminum chloride was suspended in 100 mM MES buffer at pH 4.2. The DPPC:DOPC film was 
monitored at these acidic conditions both with the buffer alone and with the buffer containing aluminum 
chloride (Figure S2). Although the presence of the aluminum ions increased the relative count of domains 
at higher surface pressures, the size distribution of the lipid domains remained in the same range, unlike 
in the case of the adjuvants, where the domain sizes increased by at least an order of magnitude, 
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compared to the control (pure DPPC:DOPC). The morphology of the lipid domains and the compression 
isotherms in both conditions were also not significantly different.  Therefore, the observed changes can be 
conclusively attributed to the particulate aluminum adjuvant and not free ions in solution.  
We speculate the altered lipid domain organization is influenced by the physicochemical 
properties of the adjuvants. While both adjuvants induced reorganization of the lipid domains, AP 
significantly increased the percentage of liquid condensed domains. These differences may be explained 
by two different effects. Much as the electrostatic characteristics of ions dictate how they interact with 
lipids, the opposite charges of the two aluminum-based adjuvants may explain their different modes of 
interaction and organization. While our results suggest the zwitterionic phosphatidylcholine can associate 
with both the positively charged AH and negatively charged AP; it is possible that the orientation of the 
dipole moment P--N+ for a PC headgroup may differ in the presence of the two different particulate 
systems. Previous nuclear magnetic resonance studies in PC systems have shown that ions which 
penetrate further into lipid layers more greatly deflect the P--N+ dipole and make the headgroup more 
perpendicular to the plane of the monolayer.26 Likewise in DOPC membranes, small cations in ion pairs 
could not only strongly interact with negative phosphate and carbonyl groups, but also oriented the 
interaction of its anion with the positive region of the head [26]. 
Therefore, we hypothesize that the differences in the compressibility modulus and the percent of 
condensed domains may be attributed to differences in the orientation of the PC headgroups, and 
therefore packing around the oppositely charged adjuvant particles. Favorable binding or electrostatic 
interactions between the positive AH and internal phosphate groups could help the particles penetrate and 
organize the phospholipids. In contrast, the phosphate-covered AP particles would attract the positively 
charged nitrogen moieties and would enhance domain growth at the air-water interface. Evidence of 
highly incorporated, disruptive AH particles in the monolayer is provided by the reduced compressibility 
modulus in our AH systems as well as Supplementary Figure S5, which shows fluorescently tagged AH 
molecules associating with the lipid membranes. Interestingly, even though significant quantities of 
tagged AP particles were found in the bulk solution, unlike the AH, most of these particulate matter was 
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not found to associate with the lipid domains, when viewed together.   These hypotheses are also 
corroborated by Figure 3 where by serving as nucleation points at the interface, AP particles allow the 
lipids to pack into larger clusters until collapse, unlike the AH particles, whose insertion eventually stunts 
domain growth beyond a certain size.  
The physical qualities of the adjuvants also provides support for the theory of monolayer 
organization by insertion vs nucleation for the AH and AP, respectively. Cho et. al. found the surface 
charge of gold nanoparticles played a large role in uptake by SK-BR-3 breast cancer cells [27]. Gold 
nanoparticles modified to have a negative charge interacted moderately well with positive patches of the 
cell surface, but positively charged nanoparticles associated significantly more with the cell membrane 
and were endocytosed. Because endocytosis occurs to maintain the charge distribution of the membrane, 
they propose the presence of the positive particles initiates changes in the rigidity and permeability of the 
membrane and promotes their internalization [27].  
Aside from charge, nanoparticle characteristics such as particle size, shape (i.e. aspect ratio), 
surface roughness and functionalization, and hydrophobicity have been shown to influence membrane 
interaction [28]. Simulations performed by Hoek et. al. suggest that surface roughness on the nanoparticle 
can enhance membrane interaction, even in some instances when the interaction would otherwise be 
unfavorable, as in the case of repulsive electrostatic or hydrophobic interactions [29]. Therefore, in 
physiological conditions where the net negative charge of the membrane may repulse the AP, the 
amorphous, rough quality of the nanoparticle could allow it to interact with phospholipids and provide a 
nucleation point for domain condensation. Additionally, experiments that studied rod- and disc-shaped 
nanoparticles demonstrated that particle aspect ratio and size are important factors in cellular uptake [30-
32]. While shorter, thin rods can still effectively cross membranes, as the aspect ratio grows the rate at 
which the particle is engulfed is reduced [31, 32]. Especially as the particle becomes wider, it becomes 
increasingly less energetically favorable for the membrane to wrap around the particle and thus may 
remain on the outer cell membrane [28, 33]. Ergo, the differences in monolayer organization could also be 
explained in light of the morphological differences between the adjuvants. Regardless of the nature of 
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either particle’s affinity for lipids, previous studies would suggest that the ability of the adjuvants to 
generate organized domains may be sufficient to organize key signaling proteins necessary to initiate an 
immune response [5, 6, 34]. Studies correlating the adjuvant-induced changes in cell signaling with the 
adjuvant-induced changes in lipid domain morphology and clustering are currently underway in our 
laboratories and will form the subject of a future work. 
4. Conclusions 
In conclusion, our results present conclusive evidence that common aluminum-based adjuvants 
Alhydrogel and Adju-Phos are both capable of reorganizing phospholipid domains in model zwitterionic 
membranes. We argue that the aluminum adjuvant-induced lipid reorganization presented here supports a 
lipid-mediated mechanism of action and thus an alternative method for enhancing immune responses. The 
pronounced effect of each adjuvant on the phospholipid domain organization was not equal, likely due to 
differences in the physicochemical properties of the adjuvant particles. The wider, negatively charged AP 
particles appeared to remain at the air-water interface, predominantly serving as nucleation points that 
allowed condensation or complexation of the zwitterionic phospholipid domains. Conversely, the positively 
charged, elongated AH particles may have helped it penetrate into the membrane, affecting the packing of 
the phospholipids and reducing the compressibility and integrity of the monolayers. The weakening of the 
monolayer in the presence of AH could explain the membrane damage and inflammation typically 
associated with the adjuvant, but it also raises further questions regarding the mechanism of action across 
different aluminum adjuvants, particularly because different forms of the adjuvant appear to produce 
disparate results in the literature.   
However, it should be noted that, while the outer leaflet of the cell membrane has been shown to 
be PC-rich, our DPPC:DOPC monolayer certainly is not fully representative of the complexity, charge, or 
compressibility of the bilayer cell membrane [23]. Our model lacks key proteins as well as signaling and 
organizational lipids found in immune cell membranes including sphingomyelin and cholesterol. As such, 
the properties of organized domains and the adjuvant-membrane interaction are expected to be markedly 
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different in a cell. Nonetheless, the persisting interaction of the adjuvants with these typically low-affinity 
phospholipids, even in the absence of cholesterol and sphingomyelin, provides an interesting starting point 
for the proposed mechanism of adjuvant-membrane interaction. The ability of adjuvants to organize and 
condense lipid domains supports the “membrane affinity triggered signaling” theory suggested for 
aluminum and monosodium urate (MSU), a product of uric acid occasionally released after cell damage by 
aluminum adjuvants [5, 34]. Although neither aluminum nor MSU crystals have receptors on DCs, previous 
studies have shown the force of the interaction can rearrange lipid domains and initiate signaling [5, 34]. 
Signaling may occur through ‘danger’ signals after membrane damage, or through proteins, such as TLRs 
and MHC II, which tend to localize in highly organized lipid domains, particularly lipid rafts [1, 8, 35, 36]. 
More complex models including organizational lipids, such as cholesterol and sphingolipids to simulate 
lipid rafts, or signal-initiating lipids, such as anionic lipids, will be necessary to help us explain how these 
adjuvants may interact with membranes and activate immune cells. Future experiments in our lab will focus 
on the effect of antigen-loaded adjuvants on phospholipid organization in model membranes, as well as 
methods to study the orientation and interaction of the adjuvants with the lipid molecules, which was not 
directly investigated in this communication. We also hope that the results presented here will motivate in-
depth structural analyses of the theorized adjuvant-induced reorganization of lipid membranes that will 
further establish the role of lipid sorting in antigen uptake and presentation.  Ultimately, understanding how 
adjuvants interact with the cell membrane could influence how we use and design novel adjuvants in the 
future. 
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Figure 1. Surface pressure (left) and compressibility modulus (right) of the DPPC:DOPC monolayer 
change as a function of mean molecular area in the presence of each adjuvant. Alhydrogel (a,b) appears to 
insert into and weaken the monolayer at higher surface pressures, while the interaction of Adju-Phos (c,d) 
does not change the mechanical properties of the monolayer. Graphs represent the average of a minimum 
of three experimental replicates. Data presented as average ± SEM. 
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Figure 2. Fluorescent images of the DOPC:DPPC model monolayer (a) alone, (b) in the presence of 
Alhydrogel, and (c) in the presence of Adju-Phos. Both aluminum adjuvants cause condensation of the lipid 
domains and drastic lipid reorganization. Images are representative of at least two individual experiments. 
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Figure 3. Distribution of the condensed domain areas in the (a) DPPC:DOPC monolayer alone and the 
monolayer in the presence of (b) Alhydrogel and (c) Adju-Phos. Addition of either adjuvant, but particularly 
Adju-Phos, increases the average area of a condensed domain by at least an order of magnitude compared 
do the DPPC:DOPC monolayer alone. (d) The percent of the image area composed of condensed domains 
is presented as a function of the surface pressure of the monolayer. Histograms were created only from the 
representative images shown in Figure 2. * p<0.05; ** p<0.01.  
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Figure S1. (a,b) Free ions present in the Alhydrogel suspension buffer are not responsible for major lipid 
sorting. Supernatant was separated from the Alhydrogel adjuvant via centrifugation as described in the 
materials and methods. The same volume of supernatant was added to the sub-phase as was used for the 
complete adjuvant formulation. (c) Relative frequency histograms show the distribution of domain areas 
produced by the DPPC:DOPC alone (black) and in the presence of the supernatant (red). (d) Surface 
pressure vs area isotherms show some interaction of the suspension buffer (green) with the DPPC:DOPC 
monolayer (blue), but Alhydrogel (in suspension buffer, black; washed, red) remains the dominant 
interaction.  
Method: To confirm that the significant lipid reorganization reported here was not due to the presence of 
free ions within the adjuvant formulation, AH particles from 1 mL of AH stock solution were separated 
from the suspension buffer via centrifugation at 10,000xg for 3 minutes. The supernatant was removed 
and reserved for further analysis. In experiments conducted with the adjuvant supernatant, a volume of 
supernatant equivalent to the volume used with the full AH stock was mixed into the ultra-pure distilled 
water sub-phase, and possible alterations in the surface morphology were monitored using fluorescence 
microscopy. 
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Figure S2. The DPPC:DOPC monolayer was spread over a subphase composed of 100 mM MES buffer 
pH 4.2. The monolayer was compressed over the subphase alone (a), and over the subphase containing 
385 μM AlCl3. The area of each domain in the representative images was calculated to create histograms 
of the domain area distributions (c) of both the monolayer alone (gray) and in the presence of AlCl3 
(purple). The compression isotherm (d) and the percent of the total image area composed of condensed 
domains (e) are derived from at least two individual experiments. 
Method: Aluminum chloride was purchased from Alfa Aesar. A MES buffered saline pack (Thermo 
Fisher) was reconstituted in distilled water to make the 100 mM MES buffer, was adjusted to pH 4.2, and 
was passed through a 0.2 μm filter. To create the aluminum ion solution, the aluminum chloride was first 
dissolved in the correct volume of subphase outside the trough to ensure thorough mixing. The molar 
concentration of aluminum present was equivalent to the concentration used in the adjuvant conditions. 
All data shown in Figure S2 is collected at pH 4.2. 
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Figure S3. The DPPC:DOPC monolayer was compressed in the presence of several concentrations of 
Alhydrogel to identify an appropriate concentration for experimentation. Compressions were generally 
insensitive to concentration, therefore the lowest concentration that had consistent interaction, 0.03 
mg/mL (diamonds), was selected. 
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Figure S4. Representative images of the trough before (a,b) and after (c,-e) imaging show no visible 
evidence of adjuvant particles settling to the bottom of the trough. Alhydrogel (a,c) and Adju-Phos (b,d) 
remain well suspended throughout the duration of an imaging experiment (approximately 45 minutes). 
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Figure S5. DPPC:DOPC spread over morin-stained adjuvants. DPPC:DOPC was spread over a 100 μL 
drop of distilled water (a) alone, (b) 0.03 mg/mL AH-morin, or (c) 0.03 mg/mL AP-morin. The morin-
stained adjuvants are observed in green. The AH particles appeared to localize in the fluid regions along 
the edges of the condensed domains, while the AP particles remained under the condensed domains. 
Images (d) and (e) show pictures of AH and AP, respectively, at 0.5 mg/mL without any DPPC:DOPC. 
 Method 
Morin was purchased from Sigma. A saturated 800 μM stock of morin was made in MOPS buffer. The 
morin stock was used to make a 1 mL solution composed of 0.5 mg Al/mL adjuvant and 250 μM morin in 
MOPS buffer and was allowed to rotate end-over-end at room temperature overnight. The stocks were 
washed by centrifuging at 3500xg for 10 minutes, removing the supernatant, and resuspending in 1 mL of 
fresh MOPS buffer. Each morin-stained adjuvant was diluted in distilled water to a working solution of 
0.03 mg Al/mL. To obtain each image, 0.5 μL of the DPPC:DOPC lipid mixture was spread over the 
surface of a 100 μL droplet of either distilled water, or the working solutions of Alhydrogel or Adju-Phos 
on a glass slide. 
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Chapter III: Aluminum Adjuvants Stabilize Lipid Raft-like 
Domains in Model Phospholipid Membranes and in 
Dendritic Cells In Vitro 
  
45 
 
1. Introduction 
Aluminum based adjuvants (ABAs) are the oldest and most prolific adjuvants, but their 
mechanism of action remains largely unknown. ABAs have been observed to promote local inflammation 
and damage at the injection site, enhanced antigen uptake, and cell migration to the site of injection and 
lymph nodes, but the molecular mechanism by which they do so is still unclear [1]. Several molecular 
mechanisms for ABAs have been proposed and contested. However, most of these theories regarding 
ABA mechanisms of action revolve around receptor-mediated mechanisms, but few have considered how 
lipid organization and non-specific membrane interactions may contribute to their adjuvanticity.    
For instance, aluminum adjuvants are suggested to activate the NLRP3 inflammasome [2, 3]. 
Danger-associated molecular patterns (DAMPs), such as monosodium urate (MSU) crystals and 
endogenous DNA, are commonly observed at the site of injection following ABA administration [4, 5]. 
The pattern recognition receptor NLRP3 is known to recognize such DAMPs, but is also proposed to 
recognize solid structures [3, 4]. After antigen presenting cells take up ABA particles or DAMPs, they 
may destabilize and rupture lysosomes, thereby freeing cathepsin-B and further activating the NLRP3 
inflammasome [3, 4]. The involvement of the inflammasome in ABA mechanism of action was thought to 
be responsible for their Th2 bias; however, several papers have also reported ABA-adjuvanticity remains 
intact even in the absence of the NLRP3 inflammasome [5]. Several other groups attribute ABA’s Th2 
bias to its initiation of the Syk-PI3 kinase pathway [6]. Interestingly, this pathway was found to be 
activated solely by interactions between ABAs or MSU and the plasma membrane of dendritic cells 
(DCs). ABAs strongly bound sphingomyelin and cholesterol, and it was hypothesized that this interaction 
initiated lipid sorting and signaling via the Syk-PI3K pathway which activated the DC and allowed it to 
endocytose antigen without the aluminum particle [7]. Although ABA phagocytosis has been confirmed 
in other cell types [8-10], the theory of initiating immune signaling by lipid sorting, particularly sorting of 
the major constituents of lipid rafts, is intriguing. 
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Lipid rafts are small, highly-ordered domains composed of sphingomyelin, cholesterol, and 
proteins [11]. Although debate surrounding the existence of lipid rafts continues, there is evidence of 
highly organized domains which greatly reduce the lateral diffusion of associated proteins, but remain 
mobile within the plane of the membrane and can cluster together to facilitate and amplify signaling 
between trapped proteins [11, 12]. Lipid rafts have been shown to provide a critical platform for 
organizing signaling proteins which participate in the immunological synapse [12-14]. The proximity of 
signaling proteins organized in the lipid rafts facilitates and propagates phosphorylation events, which in 
turn activate the cell. While there is some baseline level of phosphorylation that occurs in raft-resident 
proteins, without sufficient impetus lipid rafts do not cluster and cells are not activated [15]. 
If ABAs can promote clustering of lipid rafts and subsequently activate antigen presenting cells, 
this membrane interaction could shed light on a piece of the adjuvant’s mechanism of action. Previous 
studies reported in chapter 2 of this thesis showed both Alhydrogel (AH) and Adju-Phos (AP) could 
promote lipid clustering in a monolayer membrane composed of saturated and unsaturated 
phosphatidylcholine, a lipid for which ABAs were reported to have low affinity [7]. Here, we explore the 
interaction of these two clinically-relevant adjuvants in a more complex system composed of 
phospholipids, sphingomyelin, and cholesterol. Lipid interaction was monitored via surface pressure 
measurements and sphingomyelin and cholesterol-rich domain sorting via fluorescent imaging. Particular 
attention was given to the surface pressure of the miscibility transition, which marks the point where the 
segregated, condensed domains transition to a single homogeneous phase where all lipid components are 
mixed [16]. Consistent with our previous report, both adjuvants interacted with the lipid monolayer. Each 
adjuvant increased the miscibility transition surface pressure and stabilized lipid domains in this model 
system, but each adjuvant behaved very differently. Moreover, in vitro experiments with DCs revealed 
AH and AP could promote clustering of lipid rafts compared to control cells. Conditions which led to 
more punctate cell staining also tended to have greater secretion of TNF. Therefore, this research 
provides support for the hypothesis that ABAs may activate antigen presenting cells by promoting lipid 
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raft clustering, and that non-receptor mediated interactions may be a part of aluminum-based adjuvants’ 
mechanism of action. 
2. Materials and Methods 
2.1. Materials  
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphoethanolamine (POPE), porcine brain sphingomyelin (SM), and ovine wool cholesterol (Ch) were 
obtained from Avanti Polar Lipids, Inc. (Alabaster, AL). HPLC grade chloroform, acetonitrile and 
trifluoroacetic acid, Texas-Red DHPE, Cholera Toxin Subunit B-Alexa Fluor 555, DAPI, and ovalbumin 
(OVA) from egg white were purchased from Fisher Scientific. Alhydrogel 2% and Adju-Phos 2% were 
purchased from Sergeant Adjuvants (Clifton, NJ). 
2.2. OVA and lipid detection via HPLC-UV 
 Reversed-phase chromatographic analysis was used to measure the concentration of ovalbumin. A 
Waters HPLC system was used consisting of an e2695 separation module, a 2489 UV/Vis absorbance 
detector, and a 2414 refractive index indicator with a Waters C4 XBridge protein column (300 Å, 3.5 μm, 
4.6 x 150 mm, 10-500 K).  
Ovalbumin was detected at 220 nm. OVA elution was achieved using a gradient method where mobile 
phase A contained water + 0.05% trifluoroacetic acid and mobile phase B contained acetonitrile + 0.05% 
trifluoroacetic acid. Gradient elution was performed at 1 mL/min beginning with 5% mobile phase B until 
2.5 min, followed by 50% B at 10 min, 80% B from 18 – 20 min, and 5% B from 22 – 25 min.  
Lipids were also detected at 220 nm. Lipids were eluted from the column using a shallow gradient method 
where mobile phase A contained 5 mM phosphate buffer at pH 7.4 and mobile phase B was pure 
methanol. The gradient elution was performed at 1 mL/min beginning with 90% mobile phase B until 2 
min, followed by 97% mobile phase B from 2-12 min, then a decrease to 90% B from 17-11 min. All 
chromatograms were acquired and analyzed with Empower version 3 software. 
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2.3. Ovalbumin-adjuvant adsorption and characterization  
OVA and ABA solutions were prepared at a 1:1 ratio in 10 mM MOPS buffer (pH 7.4) and were mixed 
end-over-end at 4℃ for one hour to allow OVA adsorption. Solutions were diluted so that the final 
concentration of both adjuvant and OVA were 50 g/mL in all experiments.  
The mean particle size was measured by dynamic light scattering using a ZetaPALS (Brookhaven, 
Holtsville, NY). The amount of OVA associated with the adjuvant particle was determined immediately 
after each sample was made. 2 mL of each adjuvant-OVA solution were centrifuged at 13,000 rpm for 5 
minutes to pellet the adjuvant, and a sample was drawn from the supernatant. Free OVA was detected via 
HPLC, and the amount associated with the adjuvant was assumed to be the initial concentration added 
less the free concentration detected. Data is the average of at least 3 replicates. 
2.4. Lipid-adjuvant binding isotherms 
Stocks of each lipid were suspended in equal parts ethanol and chloroform, and were further diluted in 
ethanol to make working solutions at 2x concentration. Lipids were individually distributed to an equal 
volume of a 2x solution of either AH or AP diluted in ultrapure distilled water. Samples were vortexed 
after mixing, and again 15 minutes in to incubation at room temperature. Samples were incubated for a 
total of 30 minutes. Samples were centrifuged at 13,000 rpm for 5 minutes to pellet the adjuvant, and 
supernatants were collected and analyzed via HPLC as described. 
2.5. OVA release into water and cell culture medium 
Ovalbumin conjugated with Rhodamine B was synthesized by our lab, and used to evaluate the release of 
OVA from each adjuvant. OVA-rhodamine and AH or AP solutions were prepared as described. 
Solutions were diluted into either ultrapure distilled water (18.2 MΩ/cm; Millipore, Billerica, MA) or cell 
culture medium, and 500 L aliquots were distributed into microcentrifuge tubes. Samples were protected 
from light and incubated at room temperature on a rocking plate. At the specified time points, a tube from 
each sample was spun down at 13,000 rpm for 5 minutes to pellet the adjuvant. 200 L of the supernatant 
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was withdrawn and transferred to a black, clear-bottomed 96 well plate. Fluorescence of the released 
OVA-rhodamine was measured on a BioTek Synergy H4 plate reader (Winooski, VT) at ex/em 555/580 
nm. 
2.6. Langmuir studies 
A Langmuir trough (KSV-NIMA-Biolin Scientific, Linthicum Heights, MD) was used to measure the 
interaction of the adjuvant formulations with lipid monolayers. An equimolar 1mg/mL lipid mixture 
containing POPC:POPE:SM:Ch was suspended in chloroform. The lipid mixture was spread drop-wise 
with a Hamilton microsyringe (Hamilton, Reno, NV) to form a monolayer on the surface of an ultrapure-
distilled water sub-phase to reach a mean molecular area of 90 Å2/molecule. The monolayer at the air-
water interface was compressed symmetrically at 25 mm/minute, and the changes in the pressure of the 
monolayer were recorded using wet filter paper as a Wilhelmy plate pressure sensor. The pressure sensor 
probe was calibrated using a bare air-water interface. 1 mg/mL adjuvant solutions were diluted and 
thoroughly mixed into the sub-phase prior to spreading the POPC:POPE:SM:Ch monolayer. 
Average compression isotherms for each sample were created using GraphPad Prism 7 (GraphPad 
Software, Inc., La Jolla, CA). The compressibility modulus was calculated from the average surface 
pressure vs mean molecular area compression isotherm. The first derivative of the isotherm was obtained 
using the built-in differentiation and smoothing (second order, 5 point) tool available in Prism 7. The 
compressibility modulus is defined by 𝛽 = −𝐴
𝑑𝛱
𝑑𝐴
, where A is the mean molecular area obtained after 
smoothing. 
2.7. Fluorescence microscopy of lipid monolayers and image analysis 
To visualize the effect of the adjuvants on lipid domain formation in our model membrane system, 1 wt% 
Texas Red -DHPE (Life Technologies) was added to the POPC:POPE:SM:Ch solution. The Langmuir 
trough was placed under a custom-modified Nikon Eclipse LV100 fluorescence microscope with an 
extra-long working distance lens and tube collimators that allowed imaging of the phospholipid film 
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during monolayer compression.  Images of the lipid monolayer throughout the compression were obtained 
with an Andor Luca S camera and Solis software (Belfast, Ireland).  
The area of each condensed lipid domain was analyzed using the “Analyze Particles” tool in ImageJ 
(National Institutes of Health, Bethesda, MD). Only particles larger than 1 m2 were analyzed, and edges 
were excluded from analysis. The detected particle areas were organized and relative frequency 
histograms were created using Prism 7 software. The number of bins was calculated as the square root of 
the number of measured domains and was used to assign bin widths.  
2.8. In vitro testing of adjuvant formulations 
All formulations were tested in vitro using JAWS II cells (ATCC Manassas, VA) as a model dendritic 
cell (DC) population.  DCs were cultured according to ATCC guidelines in culture medium containing 
MEM alpha (Gibco), 20% FBS (Atlanta Biologicals), 1% penecillin-streptomycin (MP Biomedicals), and 
5 ng/mL GM-CSF (PeproTech, Rocky Hill, NJ). DCs were seeded at 2.5 x 105 cells/well in 96 well plates 
in media, or media containing 1 mg/mL OVA for priming, and were allowed to adhere overnight. The 
following morning, designated cells were activated with 100 ng/mL LPS (Sigma Aldrich) for two hours. 
All cells were washed with warmed MEM alpha, and fresh media was added to the wells. An equivalent 
volume of each formulation at 2x concentration was added to the wells to a total volume of 300 L. Cells 
were incubated at 37°C and 5% CO2. Each sample was run in duplicate, and data is the average of three 
independent experiments. 
2.9. Measurement of TNFα  
Media from each sample was collected over several time points for cytokine analysis, and was stored at    
-80°C until the time of analysis. TNFα secretion by the DCs was measured by ELISA (R&D systems, 
Minneapolis, MN) as per the manufacturer instructions. Data within each stimulation group was 
normalized to the untreated media control at 24 hours. 
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2.10. Imaging of lipid rafts in dendritic cells 
7.5 x 105 cells/well were seeded on sterilized 12 mm glass coverslips in 24 well plates and were allowed 
to adhere overnight. Cells were stimulated as described previously. Following LPS stimulation, all cells 
were carefully washed twice in room temperature complete medium. Equal volumes of unmodified 
MEM and 2x concentration treatment were added to each well to a total of 300 L and were incubated 
for 20 minutes at room temperature. In the final 5 minutes of incubation, the plate was spun down at 
350xg and 4°C for 5 minutes. The treatments were carefully removed and cells were washed twice with 
cold complete medium, and kept on ice for the remainder of the staining procedure. Cells were stained in 
a cold 1 g/mL solution of CT-B-Alexa Fluor 555/PBS and incubated on ice, protected from light for 10 
minutes. Cells were gently washed twice with cold PBS and then fixed in 2% paraformaldehyde/PBS for 
20 minutes, quenched in 25 mM glycine/PBS for 10 minutes, and washed again in PBS. Finally, cell 
nuclei were stained with 1 mM DAPI for 20 minutes and washed twice with PBS. Coverslips were 
removed from the wells and mounted on glass slides with Slowfade Gold (Life Technologies). Cells were 
examined using an inverted fluorescence confocal microscope (Olympus IX-83 motorized microscope) 
with TRITC (tetramethyl rhodamine isothiocynate) and DAPI (4',6-diamidino-2-phenylindole) filters. Z-
stacks were collected and processed with Olympus’s cellSens software. 
3. Results 
3.1. Adjuvant-ovalbumin particle characterization 
 An equal concentration of OVA and either AH or AP (50 g/mL) were mixed and the 
quantity of OVA adsorbed to the adjuvant was measured via HPLC. The OVA was completely adsorbed 
to positively charged AH due to favorable electrostatic interactions (pI OVA = 4.6 [17]), but associated 
much less (18.7 g/mL) with the negatively charged AP. Consequently, the average particle size of 
AH+OVA was 1335.6±39.5 nm, about twice that of AH alone, which was 600.1±1.5 nm. The particle 
size of AP increased only slightly; AP alone was 985.4±9.9 nm and AP+OVA was 1051.4±49.5 nm.  
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 OVA retention was also evaluated using fluorophore labeled OVA-rhodamine. OVA-
rhodamine-loaded adjuvants were diluted in conditions that replicated the conditions in the Langmuir 
trough (ultrapure distilled water) and in cell culture (20% FBS in MEM) (Fig 1). Nearly all the OVA 
was free in the AP samples both in water and media, as was expected since AP minimally associated with 
OVA. However, AH+OVA behaved differently in the Langmuir and cell culture conditions. Almost no 
OVA was released from AH in water over a time span much greater than a typical Langmuir experiment, 
but the majority of the OVA eluted from the AH within an hour of being introduced to cell culture 
medium. 
3.2. Lipid affinity differs between ABAs 
Lipid-adjuvant affinity was assessed by combining each lipid individually with AH or AP. The 
amount of lipid associated with the adjuvants was calculated as the initial amount of lipid added less the 
free lipid detected by HPLC. The maximum association, reported in mg of lipid or cholesterol per mg of 
adjuvant, is shown in Table 1. Overall, AP associated with less lipid compared to AH. AP minimally 
associated with any of the phospholipids or sphingomyelin, but associated most with cholesterol. AH did 
not retain any POPC, moderately associated with POPE, and had strong, nearly equivalent association 
with sphingomyelin and cholesterol.  
3.3. Aluminum adjuvants interact with POPC:POPE:SM:Ch monolayers 
 Bare and OVA-loaded AH and AP were well mixed into the ultrapure distilled water sub-
phase of the Langmuir trough and exposed to a monolayer containing lipids relevant to lipid rafts in a DC 
cell membrane, namely POPE:POPC:SM:Ch [7, 18]. The compression isotherms plot surface pressure 
against the mean molecular area (MMA), or the available surface area for the lipids to spread, and reveal 
bare AH and AP behave differently with the lipid monolayer (Fig 2a). AH increases the surface pressure 
compared to the lipid alone throughout much of the compression until the monolayer undergoes a phase 
transition, marked by the maximum in the compressibility modulus. The compressibility modulus is 
indicative of the monolayer’s ability to resist strain; therefore, a higher compressibility modulus is 
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representative of lipids which are more closely packed and resist being further compressed, while a lower 
compressibility modulus indicates the opposite. Additionally, since the compressibility modulus is the 
first derivative of the compression isotherm, discontinuities in its slope are obvious as minima and 
maxima, and correspond to phase transitions in the monolayer.  The compressibility modulus shows the 
membrane underwent its final phase transition into a solid state at approximately 44 Å2/molecule for AH 
and 40 Å2/molecule for lipid alone. Conversely, bare AP did not cause major deviations in compression 
isotherm compared to the lipid alone (Fig 2b). The compressibility moduli for the lipid and AP were also 
very similar. Absent the reduced maximum modulus and subtle differences at the end of the compression, 
it would appear AP did not insert into the monolayer and alter the lipid organization. This measurement of 
course, does not rule out possible association of the AP with the lipid monolayer.  
 We were also interested in how the adjuvant behavior would change in the presence of a 
model antigen, OVA. OVA on its own was very surface active, significantly increasing the surface 
pressure of the monolayer and decreasing its compressibility modulus throughout the compression. OVA 
has been previously observed to incorporate into DPPC monolayers, and was proposed to unfold such that 
its hydrophobic regions interacted with the aliphatic lipid tails, and formed aggregates which protruded 
from the monolayer with increasing surface pressure [19]. The dramatic increase in surface pressure 
observed here suggests OVA behaved similarly in this more complex lipid system, and may have 
displaced lipid from the surface. However, when OVA was adsorbed onto AH, the compression isotherm 
behavior much more closely followed that of the bare AH. On the other hand, when the monolayer was 
exposed to AP and mostly unbound OVA the monolayer’s mechanical properties more closely aligned 
with the free protein, though the AP may have inhibited some of OVA’s interaction at the interface. 
3.4. Aluminum adjuvants stabilize liquid-ordered domains in sphingomyelin and cholesterol 
containing monolayers 
To further investigate the effect of AH and AP on lipid organization, the monolayers were stained 
with Texas Red-DHPE to observe phase separation in the monolayer. In the images presented in Fig 3, 
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lipids which clustered in to a more tightly packed, liquid-ordered (Lo) phase excluded the large dye and 
appeared dark against the bright lipids in a more fluid, liquid-disordered (Ld) phase where the dye resided. 
The images presented are at the physiologically relevant surface pressure of 30 mN/m [20, 21], and at 
several points before and after the miscibility transition in this lipid mixture.  The miscibility transition 
represents the critical surface pressure at which the line tension between the Ld and Lo phases becomes 
zero, and the lipids mix to form a single phase. The surface pressures surrounding critical transitions are 
noted at the top right corner of each image. Observations of miscibility phase transitions have been well 
characterized in model membranes, including lipid bilayers, giant unilammelar vesciles (GUVs) and more 
recently in cell membrane blebs; however, it appears live cells may regulate their physical properties to 
avoid such transitions [16, 22, 23]. 
At 30 mN/m the lipid monolayer possessed smaller, round Lo domains (Fig 3a). Domain areas 
were up to 20m2, but most domains were less than 5 m2 (Fig 4a). As the monolayer was further 
compressed the domains began to grow and coalesce. At 36 mN/m, just before the lipids underwent their 
miscibility transition, the distribution of domain areas extended to 70 m2, but most domains were less 
than 30 m2. By 37 mN/m, the monolayer began its miscibility transition, marked by the blurring 
boundaries between the phases and completed within the next 1 mN/m to form a homogeneous monolayer 
like the image shown at 40 mN/m. When the bare adjuvants were added to the monolayer, the Lo domains 
were larger and persisted through higher surface pressures (Fig 3b-c). At 30 mN/m the distribution of 
domain areas exposed to either adjuvant was still centered around 5 m2 (Fig 4b-c), but extended to 
domain areas greater than observed with the lipid alone. In addition to the larger domain areas, both AH 
and AP stabilized the Lo domains and delayed the miscibility transition. The domains in the monolayer 
exposed to AP underwent similar critical fluctuations as the lipid alone, but the transition surface pressure 
was delayed to 39 mN/m (Fig 3c). Interestingly, the lipid exposed to AH did not appear to have a 
miscibility transition (Fig 3b). At 38 mN/m the condensed domains exposed to AH continued to display a 
sharp boundary, and at 39 mN/m a homogenous, dark liquid phase formed.  
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The surface activity of OVA observed in the compression isotherms was also readily visualized in 
the monolayer (Fig 3d). At 30 mN/m the mostly black frame indicated phase reversal due to the presence 
of OVA in the monolayer. Additionally, the domains had already begun the transition process, which 
completed at 32 mN/m. Although the interactions of OVA with the monolayer were observed to 
overpower those of AP in the compressibility modulus, imaging of the surface displayed AP promoted 
domain organization even in the presence of OVA (Fig 3f). While the miscibility transition of AP+OVA 
happens well before that of the AP alone (34 mN/m), it can still stabilize the Lo domains over greater 
surface pressures compared to the OVA alone. The organizational force of AH allowed it to maintain 
round, albeit much larger domains at 30 mN/m while loaded with OVA, but the presence of OVA still 
lowered the transition surface pressure compared to the bare AH (Fig 3e). 
3.5. ABAs enhance lipid raft clustering in dendritic cells in vitro 
Having studied the lipid-ABA interactions in a model lipid system, we wanted to determine 
whether the interactions were relevant in dendritic cells (DCs). DCs were either naïve (-LPS/-OVA), 
loaded and primed with OVA (-LPS/+OVA), or primed with OVA and activated with LPS (+LPS/+OVA) 
and were incubated with each sample. To observe how each treatment effected the presence and 
clustering of lipid rafts, raft-resident ganglioside 1 (GM1) was labeled using fluorescently labeled cholera 
toxin-B. Several small lipid raft patches were observed in unstimulated and untreated DCs (Fig 5a, i), but 
for the most part raft staining was minimal. In the presence of OVA (Fig 5a, ii), DCs were stained with 
slightly greater intensity and displayed greater localization of domains. Increasing levels of priming (Fig 
5b, i-ii) and activation (Fig 5c, i-ii) with and without OVA showed greater staining and domain 
clustering, with the exception of the OVA-loaded DCs where lipid raft distribution and size did not 
change with the addition of more OVA. However, addition of ABAs with and without OVA substantially 
altered the staining and clustering of lipid rafts. 
Adjuvant-treated DCs generally displayed greater lipid raft staining and clustering. Enhanced 
staining intensity was especially observed in AH-treated cells. Although there was higher signal dispersed 
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throughout the cell, -LPS/-OVA DCs treated with AH had distinct, larger patches of lipid rafts on their 
surface and around their perimeter (Fig 5a, iii). Raft polarization to the edge of the cell became more 
dramatic in AH+OVA treated cells, with lipid raft staining extending into the characteristic dendritic 
projections of the cell (Fig 5a, iv). Similar raft behavior was also observed in DCs first loaded with OVA 
and then treated with bare AH (Fig 5b, iii). OVA-loaded cells treated with AH+OVA had less dispersed 
raft staining and instead formed larger clusters of lipid rafts (Fig 5b, iv).  
Unlike the AH-treated cells, AP-treatments consistently promoted more localized clustering of 
lipid rafts, and displayed less disperse lipid raft-staining. Smaller punctate rafts in unstimulated DCs 
treated with bare AP (Fig 5a, v) grew to form larger clusters of rafts with exposure to OVA. Again, the 
behavior of lipid rafts in unstimulated DCs cultured with AP+OVA (Fig 5a, vi) and OVA-loaded DCs 
cultured with bare AP (Fig 5b, v) was similar. OVA-loaded DCs treated with AP+OVA (Fig 5b, iv) had 
the most localized lipid raft staining, showing multiple large aggregates of lipid rafts. 
Interestingly, the lipid raft distribution in the presence of the ABAs in fully LPS-activated and 
OVA-primed DCs did not necessarily match the observations in non-activated DCs. While lipid rafts in 
AH+OVA-treated cells (Fig 5c, iv) were still distributed across the surface of the DC with some punctate 
staining, DCs treated with bare AH displayed more localized small, punctate lipid raft staining (Fig 5c, 
iii). Conversely, DCs cultured with AP and AP+OVA (Fig 5c, v-vi) had larger lipid raft clusters 
compared to either of the control or AH conditions. 
3.6. Bare ABAs promote additional TNF secretion in fully activated dendritic cells in vitro 
Media from DCs treated with each sample were collected to measure concentrations of the pro-
inflammatory cytokine TNF over five days. In non-LPS activated DCs, all adjuvant formulations 
significantly increased the concentration of TNF in the medium compared to untreated and OVA-treated 
DCs after 5 days (Fig 6). -LPS/-OVA cells treated with AP or AP+OVA produced similar concentrations 
of TNF, but the bare AH produced significantly more TNF compared to AH+OVA. Contrarily, 
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differences in the concentration of TNF in -LPS/+OVA DCs cultured with AH vs. AH+OVA were 
statistically insignificant, whereas the concentration released after exposure to AP+OVA was statistically 
higher than all other treatments in the group. Unexpectedly, adding OVA to either adjuvant in 
+LPS/+OVA DCs did not result in significantly different concentrations of TNF compared to untreated 
cells, but both bare adjuvants significantly increased TNF compared to the untreated cells and free- and 
adjuvanted-OVA.  
4. Discussion 
In this study, we investigated how aluminum-based adjuvants Alhydrogel and Adju-Phos 
organize lipid raft-like domains in a model lipid system representative of dendritic cell membranes, and in 
dendritic cells in vitro. We discovered both AH and AP could promote the formation and persistence of 
liquid-ordered domains in lipid monolayers composed of an equimolar ratio of POPC:POPE:SM:Ch. The 
organizational force was strong, and could continue to enhance domain organization even in the presence 
of free or adsorbed ovalbumin, which was also highly surface active. Although both AH and AP had 
affinity for SM and Ch and stabilized condensed domains, imaging experiments and measurements of 
their interaction with the monolayer revealed dramatic differences. The increased surface pressure and 
reduced compressibility moduli of the monolayer in the presence of AH would suggest it associated with 
the lipids. Furthermore, AH-stabilized domains did not appear to undergo any critical fluctuations, nor did 
it pass through a miscibility transition. Conversely, the negligible changes induced by AP would imply it 
is excluded from the monolayer, but still stabilized condensed domains at the air-water interface and 
increased the miscibility transition surface pressure. 
Similar aluminum-based adjuvants have also been shown to have higher affinity for 
sphingomyelin and cholesterol compared to phosphatidylcholine (PC) and phosphatidylethanolamine 
(PE), which may unify some of each adjuvant’s lipid interaction [7], but the charge, surface chemistry, 
and morphology of AH and AP yield distinct behaviors. AH is a crystalline, needle-like particle with 
surface hydroxyls that provide its positive charge, whereas AP is an amorphous, disc-like particle with 
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negatively charged phosphate groups. In an experiment conducted using only zwitterionic PC lipids, 
particles of opposite charge were observed to change the orientation of the P--N+ head group with respect 
to the fatty acid tails and therefore locally alter lipid packing [24]. Positively charged nanoparticles 
preferentially interacted with the internal phosphate moiety, causing the head to become more 
perpendicular to the lipid tails and preventing adjacent lipids from packing as closely, making the 
membrane more fluid. Meanwhile, negatively charged particles interacted with the choline group and 
extended the lipid head, allowing lipids to pack more densely and gelling the membrane [24].  
Electrostatic interactions can explain AP’s ability to organize condensed domains, but its 
apparent exclusion from the membrane may be attributed to its unfavorable morphology compared to AH. 
Particles with high contact area but smaller diameters and subtle local curvature more easily associate 
with, and traverse lipid membranes because they require less curving of the membrane to be enveloped, 
and thus less disruption of lipid packing [25-27]. Simulations and model membrane systems alike have 
consistently reported thin rod or ellipsoid particles can associate with and cross membranes with greater 
ease than most particles, including spheres and discs [25-27]. Shape effects are also significant even 
within different shaped AH particles. AH particles were crystalized under different pH to produce rods, 
platelets, and polyhedra, and large, skinny rods continued to induce more robust immune responses 
compared to the other shapes [28, 29]. Therefore, the enhanced membrane perturbation observed in the 
compression isotherm of AH, but not AP is consistent with these shape-interaction trends.  
Moreover, the images of the monolayer with AH are more reminiscent of domains exposed to a 
line active impurity as oppose to domains combining at a miscibility transition. When two phases coexist, 
there is a balance between the repulsive electrostatic forces in the dipole of the condensed lipid heads, and 
the attractive forces between aliphatic chains that work to reduce the line tension at the domain boundary 
[16]. The chains of Lo phase lipids are fully extended, and extend slightly above the surrounding Ld phase. 
The hydrophobic mismatch of the chain lengths results in line tension. To reduce the thermodynamically 
unfavorable mismatch at the boundary, similar chains cluster together to form smooth, round domains, 
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limited in size by the electrostatic repulsion at the head groups [16, 30]. However, compounds may insert 
at this interface and greatly reduce the line tension, resulting in larger domains [31]. The breaking up of 
the smooth, round domains into elongated, twisting domains by AH is comparable to the reduced line 
tension caused by line active impurities in lipid membranes, and therefore further supports the presence of 
AH in the monolayer. It is also important to note that unlike the control system, which underwent a 
miscibility phase transition, the lipid domains maintained their circular structure in the presence of AH, 
suggesting a lack of transition to a single homogeneous phase. The stabilization provided by AH adsorbed 
with OVA was less dramatic, but a darker phase was still evident at 40 mN/m.  
We previously tested the interaction of AH and AP with more generic models of the outer lipid 
membrane (DPPC:DOPC) and also found AH was more associated with the membrane, while AP 
remained at the air-water interface; however, the size and shape of adjuvant-stabilized condensed domains 
were significantly different between AH and AP. The inherent organizational structure of cholesterol and 
sphingomyelin domains may explain why the condensed domains appear very similar for both adjuvants. 
Additionally, although it still appeared to be excluded from the monolayer, AP had a discernable 
interaction with the DPPC:DOPC membrane which was not observed here [32]. In addition to its 
generally low affinity for the lipids of the monolayer, the lack of AP association with the 
POPC:POPE:SM:Ch monolayer could be attributed to the enhanced rigidity typically associated with 
cholesterol and sphingomyelin-containing domains, which would more greatly resist deformation upon 
contact with an AP particle [11].  
Adjuvant-induced lipid raft clustering was also apparent in dendritic cell membranes in vitro. 
Staining for lipid rafts using cholera toxin-B showed some background lipid raft clustering of untreated 
cells, particularly in those cells which had been LPS-activated or OVA-primed, but lipid raft staining 
intensified in adjuvant-treated DCs in all activation groups. The distribution and clustering patterns of the 
rafts changed slightly depending on the activation of the cell, but AP consistently promoted large lipid 
raft clusters. Conversely, lipid raft staining was more abundant in AH-treated DCs, but rafts tended to be 
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more disperse with smaller but distinct punctate clusters of rafts. Given the behavior observed in the 
model monolayer, these images would appear to affirm ABAs preferentially interact with sphingomyelin 
and cholesterol in the DC membrane. AH, which has higher sphingomyelin and cholesterol affinity and a 
more favorable, thin-rod morphology, quickly incorporated into the membrane and enhanced more 
widespread distribution of raft staining, analogous to what was observed in the monolayer. Meanwhile 
AP facilitated more concentrated clustering of rafts from the membrane surface. If ABA’s can enhance 
similar lipid raft clustering in vivo, it is plausible that they may exert at least a portion of their adjuvant 
effect by initiating or amplifying activation-inducing or stress-mediated signaling [7, 15, 33].  
The TNF data produced by dendritic cells in different activation states also suggested a role for 
lipid interactions in aluminum adjuvanticity. As expected, all cells treated with the adjuvants had higher 
levels of the pro-inflammatory cytokine. However, in many cases the bare adjuvant particle produced an 
equivalent if not higher TNF response compared to the adjuvant with OVA. The similar response could 
be due, in part, to OVA almost entirely eluting from the adjuvants after about an hour in cell culture 
conditions, even with AH which could fully adsorb OVA in mediums without additional protein. 
Although rapid antigen elution from the adjuvant is consistent with in vivo observations [17], it is 
worthwhile to emphasize the adjuvant surface exposed to the model membranes is not necessarily 
identical to the adjuvant surface exposed to DC membranes. Nevertheless, the most compelling result was 
the +LPS/+OVA DC response to either bare adjuvant. When a DC takes up and processes an antigen or 
pathogen and makes its way to the lymph nodes to activate T cells, it begins a maturation process marked 
by significantly down regulated endocytosis, upregulated sphingolipid synthesis, and enhanced levels and 
lifetimes of raft-associated MHC-peptide complexes at the cell surface [34-36]. Therefore, fully primed 
and activated DCs would not be expected to phagocytose additional particles, but may provide more 
lipids with which the adjuvants could interact. TNF concentrations produced by +LPS/+OVA DCs were 
not significantly different between the controls and either adjuvant with OVA, but the bare adjuvants did 
promote significantly greater levels of TNF compared to all other treatments. Ergo, even though ABAs 
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likely did not enhance pro-inflammatory signaling via particle uptake, they may still have significantly 
increased TNF concentrations by clustering the lipid rafts which were more abundant in the activated 
cells. While the greatest lipid raft clustering appeared to occur with AP in +LPS/+OVA cells, further 
studies will be required to see if such an interaction is relevant in vivo, since AP has been observed to 
dissolve readily following injection [1]. 
5. Conclusion 
We have shown that the aluminum-based adjuvants Alhydrogel and Adju-Phos can interact with 
monolayers containing the major lipid components of lipid rafts, namely sphingomyelin and cholesterol. 
Although the physicochemical properties of each adjuvant differentiated how they interacted with the 
membrane, both adjuvants could form larger condensed domains compared to the lipid on its own, and 
stabilized these condensed domains, even at higher levels of membrane compression. There was also 
evidence of enhanced lipid raft clustering in dendritic cells treated with adjuvants, particularly in 
activated cells which have higher levels of sphingolipids and cholesterol. Our studies support the 
hypothesis that ABAs have a high affinity for sphingomyelin and cholesterol, and that membrane 
interaction may contribute to their mechanism of action by aggregating or stabilizing lipid rafts which can 
result in enhanced, non-receptor mediated immune activation. Our studies also reaffirm all ABAs are not 
necessarily equal, and their unique physiochemical properties may trigger different signaling pathways, 
resulting in different mechanisms of action.  
Data reported here also highlight the importance of considering the lipid environment when 
considering adjuvant effects and mechanisms of action. Our studies showed adjuvants could promote 
different levels of membrane organization depending on the activation state and lipid content of a single 
cell. Reports investigating greater membrane damage or inflammasome activation must not only be aware 
of the chemical composition of the adjuvant, but must also consider whether the studied cell population 
inherently has higher levels of lipids with which the adjuvant has higher affinity, or whether experimental 
methods which activate cells (i.e TLR activation via LPS) artificially upregulate these lipids such that 
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disruptive effects are more obvious. Therefore, these physiochemical and membrane considerations will 
be helpful in understanding and designing adjuvants to target or bolster a desired immune response.     
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Figure 1. Ovalbumin release from AH and AP in different experimental conditions. The release rate of 
OVA from each adjuvant was evaluated in cell culture medium and water. OVA did not adsorb to AP and 
was found in the supernatant nearly immediately in both medium and water. However, OVA fully 
adsorbed to AH and remained adsorbed in distilled water over the test period, while most of the OVA 
eluted off AH in cell culture medium after an hour. 
 
Table 1. Maximum affinity of adjuvant for each lipid reported in mg lipid/mg adjuvant 
Lipid Alhydrogel Adju-Phos 
POPC -- 0.92 
POPE 1.31 0.43 
Sphingomyelin 2.59 0.74 
Cholesterol 2.47 1.16 
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Figure 2. Compression isotherm and compressibility modulus of POPC:POPE:SM:Ch monolayers 
exposed to bare and OVA-loaded ABAs. (a) AH appears to associate with the lipid monolayer and disrupt 
lipid packing while (b) AP is excluded from the monolayer, but remains at the air-water interface. When 
adjuvants are loaded with OVA, AH remained the dominant force in lipid-interactions, but unbound OVA 
dominated the surface activity when delivered with AP. 
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Figure 3. Fluorescent imaging of the POPC:POPE:SM:Ch monolayer alone and in the presence of 
adjuvant formulations. Bare adjuvants not only promoted the formation of larger liquid-ordered domains, 
but also stabilized the presence of the domains through higher surface pressures. Although transition 
surface pressures decreased when adjuvants were mixed with OVA, both adjuvants could still cluster 
distinct condensed domains to surface pressures beyond the transition of OVA alone. The surface 
pressures of critical fluctuations and the miscibility transition are reported above each image. Tightly 
packed liquid-ordered lipids exclude the fluorescent dye and appear dark against a bright liquid-
disordered phase. 
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Figure 4. Liquid -ordered 
domain area distributions. The 
domain area distributions are 
shown for the bare and treated 
POPC:POPE:SM:Ch 
monolayer at 30 mN/m, and at 
the indicated surface pressures 
just prior to the miscibility 
transition. Domain areas grew 
as the compression and surface 
pressure increased, but became 
substantially larger in the 
presence of the ABAs, 
particularly AP.  
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Figure 6. Normalized concentration of TNF in the medium of treated dendritic cells at 120 hours. DCs 
were left unstimulated (-LPS/-OVA), loaded and primed with OVA (-LPS/+OVA), or primed and 
activated with LPS (+LPS/+OVA) and cultured with each treatment for 120 hours. In cells not stimulated 
with LPS, all adjuvant treatments increased the concentration of TNF compared to cells cultured with 
unmodified medium or free OVA. However, in LPS-activated DCs the bare adjuvants produced more 
TNF compared to any other treatment in the group. All measurements within each stimulation group 
were normalized to the untreated media control at 24 hours. *, p<0.05; **, p<0.01; ++, p<0.0001 
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Chapter IV: Adjuvants as Delivery Systems in Antigen-
Specific Immunotherapies 
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1. Introduction 
 Adjuvants have a long history of use in immunizations, but only recently have adjuvants been 
explored in treatments attempting to tolerize the immune system to autoantigens. Antigen-specific 
immunotherapy (ASIT) for the treatment of autoimmune disease seeks to provide targeted immune 
suppression to an autoantigen. If achievable, ASIT would provide a marked improvement to most current 
autoimmune treatments, which include anti-inflammatory, immunosuppressant, and biologic drugs [1]. 
These drugs can moderate disease symptoms, but can have serious side effects, like global immune 
suppression [1, 2]. Moreover, targeted delivery of anti-inflammatories and immunosuppressants can be 
complicated by their poor water solubility. However, with an appropriate vehicle, these drugs may be co-
delivered with an autoantigen to create a targeted ASIT. The properties of some adjuvants are amenable 
for solubilizing poorly water soluble drugs, and given the propensity of adjuvants to initiate antigen-
specific immune responses via interactions with autoimmune-relevant cell populations, adjuvants provide 
a compelling delivery system for ASIT. 
The combination of antigens and adjuvants to tolerize the immune system is not unfounded. 
Allergy shots were among the first to experiment with antigen-specific tolerization of the immune system. 
Current allergy shots ‘hyposensitize’ a patient to an allergen through subcutaneous injections of steadily 
increasing concentrations of allergen [3]. Similar approaches have been attempted with varying degrees of 
success in autoimmune diseases using adjuvanted-autoantigen.  For instance, two separate studies that 
dosed Type 1 Diabetes (T1D) patients with either aluminum-adjuvanted GAD65 or insulin b-chain in 
Incomplete Freund’s Adjuvant (IFA) showed characteristic markers of regulatory cell populations [4-6].  
When tested in other models of autoimmune disease, such as multiple sclerosis (MS), similar 
desensitization methods actually increased the risk of destructive cell activation and cytokine release, 
especially with high doses of antigen [7, 8]. These disparate results motivate further investigation and 
optimization of adjuvant-based ASIT delivery systems.  
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The capacity of adjuvants to attract and interact with cells is attractive when attempting to induce 
immune tolerance. Although the mechanism of action of adjuvants like those shown in Table 1 can vary 
greatly based on their physiochemical properties, they are all hypothesized to interact with antigen 
presenting cells (APCs), particularly dendritic cells (DCs) [9-12]. DCs are specialized APCs, and are a key 
population in ushering T cells toward activation or tolerance [13]. While DCs have been suggested to 
maintain if not induce autoimmune diseases such as T1D, MS, rheumatoid arthritis, and systemic lupus 
erythematosus [14, 15], DCs which present self-antigens without proper co-stimulation have been shown 
to promote apoptosis, anergy, and tolerogenic phenotypes in T cells [13, 15, 16]. Thus, DCs have become a 
popular target for ASIT, and are potentially accessible via adjuvant delivery. 
Both emulsions and aluminum adjuvants reported in Table 1 interact with DCs and are associated 
with promoting humoral responses, but the immune response can be skewed by delivering a second 
immunomodulatory molecule on these adjuvants. For instance, AS04 used in the HPV vaccine Cervarix 
(GSK) combines an aluminum adjuvant with monophosphoryl lipid A (MPL), a TLR4 agonist capable 
of initiating strong cellular immune responses. The combination of MPL and an aluminum salt creates 
an adjuvant system, which harnesses the strength of both components, creating strong humoral and 
cellular responses [10, 17, 18]. Potent cellular and humoral responses were also observed after enhanced 
uptake of CpG, an intracellular TLR9 agonist, in MF59 [19, 20]. Thus, an appropriate second molecule 
can expand the utility of traditional adjuvants and help shape downstream immune responses.  
Following this same rationale, adjuvants which deliver an appropriate secondary signal should 
also be a valuable tool for promoting immune tolerance. Dexamethasone (DEX) has been categorized as a 
classic immunosuppressant currently used to treat autoimmunity and has also been found to promote 
immune tolerance. For instance, DEX has been used to create ‘tolerogenic DCs’ [21, 22], and DEX-treated 
DCs have been shown to enhance expression of tolerance-promoting factors in T cells [21, 23]. One 
method for generating ‘tolerogenic DCs’ requires treating the DCs with DEX and an activating stimulus, 
which may be achieved by the combination of adjuvant and DEX. Furthermore, DEX is a poorly soluble 
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glucocorticoid with intracellular receptors, therefore delivery with an adjuvant could help it to traverse the 
cell membrane and reach its site of action [24, 25].  
In this study, we evaluated several common adjuvants (Table 1) as vehicles to co-deliver 
dexamethasone and a model antigen, ovalbumin (OVA). The release of DEX from adjuvants was 
investigated, and the effect of adjuvant, DEX, and OVA was tested in vitro using a DC line. An MF59 
analog made in our lab was then advanced to co-culture studies using OVA-primed bone marrow-derived 
dendritic cells (BMDCs) and splenocytes from OT-II mice. 
2. Materials and Methods 
2.1. Materials 
Ovalbumin, bovine serum albumin (BSA), Tween 80, Incomplete Freund’s Adjuvant (IFA, DIFCO 
Laboratories), MEM alpha, RPMI, resazurin (Acros Organics), phalloidin-AlexaFluor 568 (Molecular 
Probes), DAPI (Molecular Probes), Slowfade Gold (Life Technologies), 2-mercaptoethanol, and HPLC 
grade acetonitrile, trifluoroacetic acid, and dimethyl sulfoxide (DMSO) were purchased from Fisher 
Scientific. Dexamethasone, squalene, Span 85, lipopolysaccharide (LPS, E. coli), and red blood cell 
lysing buffer were purchased from Sigma.  
2.2. Model antigen and secondary signal 
Ovalbumin (OVA) served as the model antigen and was used at a final concentration of 50 g/mL. A 10 
mg/mL stock of OVA was prepared in ultrapure distilled water (18.2 MΩ/cm; Millipore, Billerica, MA). 
Dexamethasone (DEX) was used at a final concentration of 100 nM. A 100 M stock of DEX was 
prepared in HPLC grade DMSO. 
2.3. MF59 analog preparation 
The MF59 analog (MF59a) used in these experiments was prepared based on methods published by 
Novartis (18390722).  To prepare the emulsion the oil phase, composed of 39 mg/mL squalene and 4.7 
mg/mL Span 85, was combined with the aqueous phase containing 4.7 mg/mL Tween 80 in 10 mM 
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citrate buffer (pH 5.5). The solution was then emulsified on ice for 2 minutes with pulsing (10 seconds 
on, 2 seconds off) at 50% amplitude using a probe sonicator (Sonics Vibracell, Newton, CT). The 
solution was then passed through a 0.22 m PES filter (Millipore Cork, IRL) and stored in a glass vial at 
4°C. 
2.4. Antigen and dexamethasone formulations 
All formulations were prepared at 2x concentration, and were diluted in cell culture medium or buffer, 
depending on the experiment. Alhydrogel (AH) and Adju-Phos (AP) (Brenntag, Denmark) based vaccines 
were used at a final concentration of 50 g Al/mL. These adjuvants were combined with OVA (final 
concentration, 50 g/mL) and/or DEX (100 nM for JAWS, 1 nM for BMDCs) in 10 mM MOPS buffer 
(pH 7.4) and were mixed end-over-end at 4°C for one hour.  
The MF59a was prepared as described and was diluted to make formulations containing 5% MF59a by 
volume in experiments with JAWS II, and 1% by volume in experiments with BMDCs. MF59a+DEX 
formulations were made by mixing a DEXDMSO into the oil phase prior to sonication, and in relevant 
formulations OVA was present in the diluting medium. IFA was emulsified in MOPS buffer by passing 
the solution through a 20G emulsification needle. OVA was mixed into the buffer and DEXDMSO was 
mixed into the IFA prior to emulsification. Final IFA formulations contained 10% IFA by volume and 
were used immediately after emulsification. 0.1% DMSO by volume was present in all formulations. 
2.5. OVA and DEX detection via HPLC-UV 
OVA and DEX concentrations were measured by reversed-phase chromatographic analysis. A Waters 
HPLC system was used consisting of an e2695 separation module, a 2489 UV/Vis absorbance detector, 
and a 2414 refractive index indicator with a Waters C4 XBridge protein column (300 Å, 3.5 μm, 4.6 x 
150 mm, 10-500 K).  OVA and DEX were detected at 220 nm and 240 nm, respectively. Separation was 
achieved using a gradient method where mobile phase A contained water + 0.05% trifluoroacetic acid and 
mobile phase B contained acetonitrile + 0.05% trifluoroacetic acid. Gradient elution was performed at 1 
76 
 
mL/min beginning with 5% mobile phase B until 2.5 min, followed by 50% B at 10 min, 80% B from 18 
– 20 min, and 5% B from 22 – 25 min. Chromatograms were acquired and analyzed with Empower 
version 3 software.  
2.6. OVA and DEX association and particle sizing 
The mean particle size was measured by dynamic light scattering using a ZetaPALS (Brookhaven, 
Holtsville, NY). The amount of OVA or DEX associated with the adjuvant particle was determined 
immediately after each sample was made, and was calculated based on the free OVA or DEX in solution. 
In the AH and AP solutions, 2 mL of each solution were centrifuged at 13,000 rpm for 5 minutes to pellet 
the adjuvant, and a sample was drawn from the supernatant. Samples of each emulsion vaccine were 
centrifuged in an AccuSpin 3R fixed upright at 2850xg for 20 minutes at 10°C to separate the oil and 
aqueous phases, and a sample was carefully drawn from the aqueous phase below. To concentrate the 
DEX samples they were frozen, lyophilized, and reconstituted in 50:50 acetonitrile:water. Free OVA and 
DEX were detected via HPLC, and the amount associated with the adjuvant was assumed to be the initial 
concentration added less the free concentration detected. Data is the average of at least 3 replicates. 
2.7. Dexamethasone release 
To determine how dexamethasone was released from the formulations with time, samples were placed in 
Slide-A-Lyzer MINI-Dialysis devices (10 MWCO, Thermo). Each device was suspended in a 15 mL 
beaker such that the bottom of the cup was approximately in the middle of the PBS dialysis buffer (pH 
7.4). Each beaker was covered in parafilm to prevent evaporation and was placed in an incubated shaker 
(New Brunswick Scientific) set at 37°C and 80 rpm. At each time point, half the dialysis buffer was 
removed for analysis via HPLC and was replaced with an equal volume of fresh, warmed buffer. 
To ensure DEX was detected in the dialysis buffer, samples were concentrated on the HPLC column via 
trace enrichment. Briefly, multiple injections of each sample were made using an isocratic method (95% 
Mobile Phase A: 5% Mobile Phase B) to load DEX on to the column, followed by a final injection using 
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the gradient method to elute the DEX. Samples collected before 24 hours were injected a total of four 
times, all others were injected twice. 
2.8. In vitro testing of vaccines in JAWS II 
All formulations were tested in vitro using JAWS II cells (ATCC Manassas, VA) to create a model 
dendritic cell (DC) population.  DCs were cultured according to ATCC guidelines in culture medium 
containing MEM alpha, 20% FBS (Atlanta Biologicals), 1% penicillin-streptomycin (P/S, MP 
Biomedicals), and 5 ng/mL GM-CSF (PeproTech). DCs were seeded at 2.5 x 105 cells/well in 96 well 
plates in media, or media containing 1 mg/mL OVA for priming and were allowed to adhere to the plate 
overnight. The following morning, designated cells were activated with 100 ng/mL LPS for two hours. 
All cells were washed with warmed MEM alpha, and fresh media was added to the wells. An equivalent 
volume of each formulation at 2x concentration was added to the wells. Plates were incubated at 37°C 
and 5% CO2. Each sample was run in duplicate, and data is the average of three independent experiments. 
2.9. Bone marrow-derived dendritic cell isolation and differentiation  
Five-week-old C57BL/6J mice were purchased from Jackson Laboritories and housed under specified, 
pathogen-free conditions at The University of Kansas. All protocols involving mice were approved by the 
Institutional Animal Care and Use Committee at The University of Kansas. Mice were sacrificed and their 
femurs were collected. The ends of the femur were clipped, and the bone marrow was flushed out using a 
21-gauge needle attached to a 5 mL syringe containing RPMI supplemented with 1% P/S. Cells were 
collected and centrifuged for 7 minutes at 1,350 rpm at 4℃. The supernatant was removed, replaced with 
red cell lysis buffer, and incubated at room temperature for 10 minutes. Lysis was stopped with 6x 
volume of cold complete medium (RPMI, 10% FBS, 1% penicillin-streptomycin, 50 mM 2-
mercaptoethanol). The cell solution was passed through a 70 m nylon cell strainer and centrifuged for 5 
minutes at 1,700 rpm and 4℃. The supernatant was removed and replaced with complete medium, and 
cells were plated at approximately 2x106 cells per T-75 culture flask in 12 mL complete medium spiked 
with 20 ng/mL GM-CSF. On day 3, the medium was removed to discard any floating cells, and 12 mL of 
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media with fresh GM-CSF was added to the cells. On day 8, the media with suspension cells were 
collected and the bottom of the flask was thoroughly rinsed to collect any loosely adherent cells. BMDCs 
were ready for treatment. 
2.10. Treatment of BMDCs and co-culture with OT-II splenocytes 
3x106 BMDCs for each treatment group were distributed to T-75 culture flasks. Medium was added to 
unstimulated BMDCs, and OVA-primed BMDCs were cultured with 1 mg/mL OVA prior to treatment as 
before. BMDCs were rinsed and then treated for two days. To maintain viability of the cells, primary 
BMDCs were treated with 1 v/v% MF59a and 1 nM DEX. After two days of treatment, BMDCs were 
collected and plated at 5x105 cells/well of a 96 well plate.  
OT-II transgenic mice (B6.Cg-Tg(TcraTcrb)425Cbn/J) were purchased from Jackson Laboratories, and 
were sacrificed at approximate 7-weeks of age. Spleens were harvested and passed through a 70 m nylon 
mesh fitted over a 50 mL tube containing 5 mL of cold RPMI+1% P/S. Cells were centrifuged for 7 
minutes at 1,350 rpm and 4℃. The supernatant was removed, replaced with red cell lysis buffer, and 
incubated at room temperature for 7 minutes. Lysis was stopped with 6x volume of cold complete media 
(RPMI supplemented with L-glutamine, 10% FBS, 1% P/S), and the solution was passed through another 
nylon strainer and centrifuged again as before. Cells were suspended in fresh medium, counted, and 
distributed to the 96 well plate containing the BMDCs at 5x105 cells/well. 
2.11. Metabolic Activity 
Cell viability was inferred from metabolic activity measured by the resazurin assay. Wells were washed to 
remove as much of the formulations as possible and 100 µL of clear MEM alpha and 20 µL of 0.01% 
resazurin were added to the wells. Plates were incubated at 37°C for one hour, and the fluorescence was 
measured at ex/em 560/590 nm using a SpectraMax M5 plate reader (Molecular Devices, Sunnyvale, 
CA). Data within each stimulation group was normalized to the untreated media control at 24 hours. 
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2.12. Measurement of cytokines 
 Media from each sample was collected over several time points for cytokine analysis, and was stored at -
80°C until the time of analysis. TNFα secretion by the JAWS II DCs was measured by ELISA (R&D 
systems, Minneapolis, MN) as per the manufacturer instructions. Data within each stimulation group was 
normalized to the untreated media control at 24 hours within an experiment. In the co-culture 
experiments, several cytokines were measured using a U-PLEX kit (Meso Scale Diagnostics, LLC, 
Rockville, MD) as per the manufacturer instructions. Data within each treatment was normalized to the 
unprimed, untreated media control at 24 hours, and was also normalized to the average metabolic activity 
of each treatment at each timepoint. 
2.13. Dendritic cell imaging 
6 x 105 cells/well were seeded on sterilized 12 mm glass coverslips (Fisher Scientific) in 24 well plates 
and were allowed to adhere overnight. Cells were stimulated and treated as described previously. After 
120 hours the culture medium was removed, cells were washed in PBS, and fixed in 2% 
paraformaldehyde/PBS (Electron Miroscopy Sciences) for 10 minutes. Cells were then quenched in 25 
mM Glycine/PBS for 5 minutes, permeabilized in 0.05% Triton X-100/PBS for 15 minutes, and were 
blocked with three washes of 1% BSA/PBS. Cells were simultaneously stained in 0.165 mM phalloidin-
AlexaFluor 568 and 1 mM DAPI in 1% BSA/PBS for 20 minutes. After staining, cells were washed two 
times each in PBS and distilled water. Coverslips were removed from the wells and mounted on glass 
slides with Slowfade Gold. Cells were examined using an inverted fluorescence confocal microscope 
(Olympus IX-83 motorized microscope) with TRITC (tetramethyl rhodamine isothiocynate) and DAPI 
(4',6-diamidino-2-phenylindole) filters. Images were collected and processed with cellSens software. 
2.14. Statistical analysis 
Statistical analysis was performed using GraphPad Prism 6 (GraphPad Software, Inc., La Jolla, CA ). 
Data were analyzed via two-way ANOVA in conjunction with Tukey’s test. P-values less than 0.05 were 
considered significant. 
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3. Results 
3.1. Vaccine particle characterization 
  The ability of each adjuvant to carry OVA and DEX was investigated via HPLC (Table 2). 
The 50 g/mL of OVA in solution was completely adsorbed to AH, but associated much less with AP, 
and minimally with either emulsion. Conversely, both emulsions, particularly MF59a, could retain most 
of the 100 nM DEX added to the formulation, while neither aluminum adjuvant retained any. The particle 
size of the formulations containing an aluminum adjuvant was generally around a micron, whereas 
MF59a spanned approximately 230–300 nm, and IFA vaccine particles were about 130 nm. 
3.2. Dexamethasone release from emulsions 
 Free DEX and DEX+adjuvant solutions were added to dialysis devices to determine the rate 
of release of DEX. The release of DEX was determined by measuring the concentration of free DEX in 
the PBS dialysis buffer. Within the first six hours of the experiment, the release of DEX was not 
statistically different between any of the groups (Fig 1b), but the trends indicated DEX release from 
MF59a was the slowest. After 24 hours, significantly less DEX was detected from the MF59a samples 
compared to the free DEX (Fig 1a). After 48 hours, the differences in DEX release were statistically 
significant between both emulsions and the free DEX. At no point in the study was the release profile of 
AH+DEX different than the free DEX.  
3.3. In vitro testing of formulations  
 All combinations of adjuvant, OVA, and DEX were tested in vitro in a JAWS II-derived DC 
system. The DCs were either antigen-primed (-LPS/+OVA), LPS-activated (+LPS/-OVA), primed and 
activated (+LPS/+OVA), or left naïve (-LPS/-OVA). The concentration of TNF from each sample was 
normalized against the 24 hour media control within each stimulation group. The baseline response of 
DCs across the groups, measured by the amount of pro-inflammatory cytokine TNF, was first tested 
with the adjuvants alone (Figure 2). 
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 In all DC groups, the aluminum adjuvants significantly increased levels of TNF after 72 
hours. In the non-LPS-activated conditions (Figure 2a,b), the cells incubated with AH or AP for 120 
hours produced significantly more TNF than the untreated cells, and at least 10 times more TNF than 
the same cells at 24 hours. Conversely, the emulsions generally did not produce TNF in significantly 
greater quantities than the untreated cells throughout the span of the experiment, and in several instances 
even maintained significantly lower concentrations than the untreated cells (Figure 2c,d). The viability of 
the adjuvant-treated cells was comparable to the untreated cells, except for the MF59a group, whose 
metabolic activity consistently waned after 72 hours. The viability of the +LPS/+OVA cells treated with 
IFA was lower than the control throughout the experiment (Figure 2d). 
 The DC response to the more traditional adjuvant-antigen particle was also tested. As 
expected, the aluminum adjuvants with OVA created a significant pro-inflammatory response in the cells, 
particularly the –LPS/-OVA and –LPS/+OVA cells (Figure 3a,b). In the OVA-primed cells, the 
aluminum-adjuvanted OVA prompted at least 10-times more TNF than the untreated cells after 72 
hours. In contrast, none of the DC groups cultured with either emulsion produced more TNF than the 
OVA alone. TNF levels where consistent among all adjuvants with OVA in the LPS-activated 
conditions (Figure 3c,d). The normalized concentration of TNF in these samples was close to 1, and 
therefore similar to the concentration of their respective 24 hour media control over the span of the 
experiment. There were no significant differences between the OVA alone or any of the formulations. 
Trends in metabolic activity were similar to the cells treated with adjuvant alone, but with improved 
metabolic activity in the emulsions.
 When free DEX was added to the DCs, the concentrations of TNF remained approximately 
equal to the 24h media concentration within the respective stimulation groups (Figure 4). The addition of 
DEX also mitigated the inflammatory effect of AH and AP observed previously with and without OVA. 
Despite the greatly reduced effect of the aluminum adjuvants in the presence of DEX, AP still induced 
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significantly more TNF than the DEX alone after 120 hours regardless of stimulation with LPS or OVA. 
Apart from the cells primed only with OVA (Figure 4b), the DC response to DEX delivered in the 
emulsions was statistically equivalent to free DEX. TNF response again seemed homogenous in the 
LPS-activated groups. 
 Finally, formulations containing adjuvant, OVA, and DEX were tested with the DCs. In the 
DCs not activated with LPS, the presence of DEX in the formulation greatly inhibited TNF production 
compared to the adjuvant with and without OVA, especially in the case of AH and AP. Even still, in the  
–LPS DCs, cells treated with AP+OVA+DEX generated significantly more TNF than those treated with 
the unadjuvanted co-administered OVA+DEX (Figure 5a, b).  MF59a with OVA+DEX never produced 
significantly more TNF than the OVA+DEX at any of the sampled time points in any DC group, and 
IFA-based formulations only produced more after 120 hours in the OVA-primed DCs with and without 
LPS stimulation (Figure 5b,d). The DCs which were only primed with OVA produced more TNF in 
response to the treatments compared to the naïve DC, but both the +LPS/-OVA and +LPS/+OVA DCs 
responded similarly to the formulations containing all components (Figure 5c,d). As previously observed, 
the stimulatory effect of the adjuvants appears to be absent in the LPS-activated DCs in that the 
formulations did not behave differently than the free components and there were no differences in 
response between the formulations, with the exception of the AP+OVA+DEX vaccine after 120 hours 
(Supplementary Fig 1).  
 In nearly every formulation and activation state, DEX overcame the increase in TNF caused 
by the adjuvant with and without OVA. When the different treatment combinations of a single adjuvant 
were evaluated within a stimulation group, there was only one instance of a significant difference 
(+LPS/+OVA DC’s with MF59a at 72 h) between the DEX and the OVA+DEX treatments over 120 
hours of culture (Supplementary Fig 2). In nearly every adjuvant and activation state, the levels of 
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TNFproduced by the formulations containing adjuvant+OVA+DEX were significantly less compared to 
the adjuvant+OVA by 120 hours. 
3.4. Fluorescent imaging of treated ±LPS/+OVA DCs  
 After 120 hours of culture, activated and non-activated OVA-primed DCs were fixed and 
actin-stained to observe how different treatments altered their morphology. Untreated –LPS/+OVA DCs 
were fairly round and gathered into colonies (Figure 6). Culture with free or adjuvanted OVA for 120 
hours made the cells notably larger, and in the case of free OVA even more densely packed. AH+OVA 
and AP+OVA-treated cells had spread out on the glass slides and strands of actin-highlighted dendrites 
and veils were visible on the cells, morphology indicative of activation. In fact, evidence of this activated 
morphology could be observed in all adjuvanted-OVA samples. When the -LPS/+OVA cells were treated 
with free or adjuvanted-DEX, the cells somewhat recovered the size of the untreated cells without 
recolonizing; although there was evidence of activation in the free DEX-treated cells. Veils could be 
observed in both aluminum+DEX treated groups; however, the AH+DEX DCs had similar morphology 
and size as the free DEX DCs, while the AP+DEX-treated cells remained large. The emulsions behaved 
differently, particularly the MF59a+DEX treated cells which adopted a small but oblong morphology. 
Unlike the MF59a+DEX cells, the IFA+DEX cells had uneven pockets of high-intensity actin staining. 
When OVA and DEX were co-delivered, the cell did not show an activated morphology, like the OVA-
treated cells, but were similar in size.  
 Unlike the –LPS/+OVA cells, the untreated +LPS/+OVA cells shown in Figure 7 adopted a 
more activated morphology as they spread out and extended long dendrites. When these cells were 
cultured with free or adjuvanted-OVA, large colonies were again observed and the cells became much 
larger. Each group of +LPS/+OVA cells treated with adjuvanted-OVA displayed strong signs of 
activation, more so than the -LPS/+OVA cells. Addition of DEX again reduced the activated morphology 
of the cells, but did not eliminate evidence of activation in the free, AP-, or IFA- adjuvanted DEX groups. 
AH+DEX and MF59a+DEX treated cells regained the rounded shape of unactivated DCs. The 
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combination of free OVA+DEX in these cells appeared to activate more than subdue these cells, 
producing actin-polarized cell membranes and regions of uneven, high-intensity staining.  The aluminum-
adjuvanted OVA+DEX cells fared slightly better, showing less actin polarization and a more rounded 
shape compared to the free OVA+DEX. The low metabolic activity of IFA+OVA+DEX-treated cells 
reported by the resazurin assay in Figure 4d was observed in cells with damaged or absent cytoskeletons. 
The MF59a+OVA+DEX showed visible signs of having the least activated cell morphology in this group, 
although there was still evidence of membrane damage. The morphology of the cells treated with AH- 
and MF59a-adjuvanted DEX and OVA+DEX also suggests these treatments may have been more 
effective in reducing the activation of +LPS/+OVA DCs than indicated by the TNF  
3.5. Coculture of MF59a-treated BMDCs with OT-II splenocytes 
 Based on its ability to slowly release DEX, maintain good viability, and decrease activation 
of DCs, MF59a was selected for further investigation in co-culture. Primary cells tend to be less robust, 
therefore to maintain the viability of these cells, they were treated with less MF59a (1% by volume) and 
DEX (1 nM). -LPS/+OVA BMDCs were treated for two days, washed, and then cocultured with 
splenocytes obtained from OT-II transgenic mice, which have an enhanced population of CD4+ T cells 
that primarily recognize OVA323-339. Metabolic activity of the cells cocultured with OVA-primed and 
MF59a-treated BMDCs was consistently lower than the activity of the unprimed, untreated BMDC 
coculture (Fig 8), but the viability of the coculture was improved in groups where DEX was delivered in 
MF59a compared to free DEX. 
 Cytokine data revealed DEX delivered in MF59a could also mitigate the production of pro-
inflammatory cytokines as well as the free DEX. In fact, in all the tested cytokines there was no 
significant difference in cytokine concentration when DEX or OVA+DEX was free or delivered in 
MF59a. After 72 hours, TNF concentrations were significantly reduced in both MF59a+DEX and 
MF59a+DEX+OVA cocultures compared to those left untreated or treated with OVA (Fig 9). IL-2 and 
GM-CSF, cytokines indicative of T cell and monocyte proliferation and activation, respectively, were 
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increased in MF59a+OVA+DEX samples compared to MF59+DEX alone and was not different from 
MF59a+OVA (Fig 10 a,b). However, concentrations of the TH1 polarizing cytokine IFN were not 
significantly different between the MF59a+DEX groups, and there was significantly less IFN in both 
samples compared to MF59a+OVA (Fig 10c). Furthermore, no significant differences in IL-4, a TH2 
polarizing cytokine, were found between any MF59a treatments (Fig 10d). Only free DEX significantly 
increased concentrations of the anti-inflammatory cytokine IL-10 (Fig 10e). 
4. Discussion 
 Adjuvants have longstanding success helping to initiate antigen-specific immune responses, 
but little has been done to determine whether adjuvants could be part of a strategy to target and quell an 
autoimmune response. Immune cells like DCs play key roles in initiating immune responses and 
maintaining tolerance, and they are among the primary targets of most adjuvants [13, 26]. Therefore, 
adjuvants could be an excellent means to deliver small doses of antigen and a secondary signal, such as an 
immunosuppressant, to this key population of cells and downregulate their response to the antigen.  
 While each adjuvant was meant to co-deliver the model antigen OVA and DEX, each 
adjuvant was found to carry one component better than the other.  Neither aluminum adjuvant carried 
DEX and neither emulsion adjuvant retained OVA; however, neither emulsion was expected to associate 
with OVA based on publications with other antigens. Moreover, antigen association is not required to 
create antigen-specific immune responses in emulsion adjuvants like MF59 [12, 27, 28]. Conversely, the 
hydrophobic components of each emulsion allowed them to solubilize DEX.  Furthermore, IFA and 
MF59a extended the release of the drug, with MF59a prolonging its release most. Delivery of poorly 
soluble drugs in emulsions is not completely unprecedented, especially in oral formulations. The cancer 
drug paclitaxel and the immunosuppressants cyclosporine A and tacrolimus have all been formulated in 
emulsions to improve their solubility [29-31]. Delivery of these drugs in emulsions reduced their side 
effects, prolonged their release, and improved their uptake due to the enhanced cell permeability provided 
by the oil and surfactant [29-31]. 
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 The formulations capable of delivering DEX were better at suppressing TNF production in 
JAWSII DCs. DEX effectively combated the TNF stimulated by any adjuvant and OVA, but the 
concentrations were lowest in the emulsions. Moreover, the least activated morphology was observed in 
DCs treated with formulations containing MF59+DEX [32]. DEX exerts some of its 
immunosuppressant activity as an antiproliferative agent, which is reflected in the metabolic activity of 
each of the treatments [24]. The metabolic activity plots of free DEX delivered with and without either 
aluminum adjuvant are similar, but differ from those of the emulsions, particularly MF59a, which may be 
an indication of the sustained release and enhanced membrane permeability provided by the squalene and 
surfactants [33, 34]. Although IFA also moderately extended the release of DEX, the short chain fatty 
acids in IFA have been observed to have detergent effects which can cause cell lysis [35, 36]. The lytic 
effects of IFA could have been responsible for the consistently low metabolic activity and cytoskeletal 
damage seen in IFA+DEX treated cells.  
 Although aluminum adjuvants have been used to tolerize the immune system to an auto-
antigen [5], our results indicate they remain better suited for immune-activating applications. In addition 
to neither carrying nor sustaining the release of DEX, the particulate nature of AH and AP and their 
ability to stimulate DCs via lipid interactions likely caused them to consistently produce higher levels of 
TNF compared to the other treatments at all levels of activation [37-39]. Although AH and AP 
significantly increased concentrations of TNF in all activation groups, the treatments predominately 
affected DCs not exposed to LPS. LPS activation matures DCs and drastically reduces their endocytic 
ability, meaning they are less likely to take up the treatments [40]. Also, the normalization of the +LPS 
TNF values may be somewhat misleading in that the TNF concentration in these cells was often at 
least twice that of -LPS DCs. Thus, the normalized concentrations do not appear to vary greatly because 
of the sustained elevated TNF levels. It is also possible the concentration of DEX used was insufficient 
to combat the robust activation. Although the morphology of +LPS/+OVA disease revealed DEX 
delivered in MF59a or with AH may have been moderately effective in reducing the activation of the 
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DCs. Since TNF did not reflect this reduction in activation, monitoring additional cytokines such as IL-
12, IL-10, and TGF would be helpful to better characterize the DC response to adjuvant-based ASITs in 
the future. Regardless, the studies with JAWS II DCs indicated MF59a, which was initially conceived as 
a delivery vehicle for lipophilic muramyl peptide MTP-PE [41, 42], was the best option for co-delivery of 
OVA and DEX. 
 The beneficial effects of co-delivering DEX and OVA in MF59a to OVA-loaded BMDCs 
were maintained in ex vivo experiments with primary cells. Although the cytokine concentrations did not 
differ significantly when DEX or OVA+DEX was delivered in MF59a, the viability of the co-culture was 
greater in the MF59a samples. Despite the enhanced proliferation indicated by the resazurin assay and the 
higher levels of IL-2 and GM-CSF, cytokine concentrations normalized to the metabolic activity revealed 
the addition MF59a did not augment the TH1 or TH2 polarizing cytokines IFN and IL-4, respectively. 
MF59 tends to promote TH2 responses, ergo the lack of IFN was expected, but the lack of IL-4 
upregulation would suggest the full activity associated with clinical MF59 was overcome in these 
experiments [42]. IL-10 concentrations were not significantly enhanced in any of the MF59a samples, but 
that does not preclude the potential presence of other cytokines which promote regulatory populations, 
such as TGF1 [43]. 
  Further studies will be required to determine the presence of these and other tolerance-
promoting factors, but BMDCs treated with either MF59a+DEX formulation showed promise for use in 
ASIT. In vitro, tolerogenic DCs could be created from BMDCs which were semi-matured by treatment 
with both a suppressing and activating agent [43, 44]. Tolerogenic DCs were maturation-resistant, 
enhanced anti-inflammatory cytokine synthesis, impaired synthesis of TH1 cytokines, could migrate to the 
secondary lymph nodes, and could present antigen to antigen-specific T cells [43]. In vivo experiments 
will be required to evaluate whether adjuvant-based ASITs can enhance DC migration to the lymph 
nodes, but MF59 has been shown to greatly enhance the migration of antigen- and adjuvant-loaded 
immune cells to the lymph nodes [9, 45]. Additionally, emulsion formulations with other poorly soluble 
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drugs have been found to enhance their immunomodulatory activity by promoting their transport to the 
lymphatics and exposure to lymphocytes [46]. Therefore, emulsions like MF59 could hold promise for 
ASITs aiming to co-deliver auto-antigen and poorly-soluble immunomodulatory drugs. 
5. Conclusions  
 Adjuvants have been exceedingly successful in creating pro-inflammatory, antigen-specific 
immune protection, but they also have the potential to serve as efficient vehicles in antigen-specific 
immunotherapies which promote immune tolerance. In these experiments, we sought to create an 
adjuvant-based ASIT to provide targeted delivery of an antigen, ovalbumin, and an immunomodulatory 
molecule, dexamethasone, to promote antigen-specific suppression in antigen-competent immune cell 
populations. We found both IFA and the MF59 analog produced in our lab solubilized the poorly-soluble 
immunosuppressant, but MF59a carried the most DEX and provided the most extended release of the 
drug. DEX delivered in MF59a also successfully mitigated the pro-inflammatory properties of both the 
adjuvant and OVA in dendritic cells. Furthermore, in co-culture with splenocytes from OT-II transgenic 
mice, BMDCs treated with formulations which included MF59a and DEX continued to reduce pro-
inflammatory cytokines as well as free DEX formulations.  MF59-based ASITs require further testing in 
vivo; however, their prospect for success is promising. MF59-based ASITs may not only enhance 
targeting of antigen and drug to immune populations of interest, but their ability to contain and slowly 
release poorly soluble drugs would also imply there is less risk for off-target interactions and side effects 
typically associated with these drugs. Therefore, the utility of emulsion adjuvants could be expanded 
outside their conventional realm of prophylactic vaccination, and should continue to be investigated as 
delivery vehicles in antigen-specific immunotherapy for autoimmune diseases. 
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Table 1. Properties and mechanisms of common adjuvants 
Adjuvant Class 
Size 
(nm) 
Ag association with 
adjuvant 
Mechanisms of action Ref 
Alhydrogel Particulate ~15000 
Electrostatically adsorbed, 
Covalently bound 
Enhanced phagocytosis, 
Causes membrane damage & 
inflammation, 
Immune cell recruitment 
[47] 
Adju-Phos Particulate ~5000 
Incomplete 
Freund’s 
Adjuvant 
Emulsion Variable 
Free in aqueous phase, 
Adsorbed at interface 
Forms depot, 
Drain to lymph 
[48] 
MF59 Emulsion 160 
Create ‘immunocompetent’ 
environment, 
Enhanced uptake, 
Drain to lymph, 
Membrane 
permeabilization/damage 
[9, 
12, 
33, 
45] 
 
 
Table 2. Vaccine particle characterization 
Adjuvant 
 
Ovalbumin (µg/mL) Dexamethasone (nM) Size (nm) 
Alhydrogel 
OVA 50 -- 1335.6 ± 39.5 
DEX -- 0 600.1 ± 1.5 
OVA+DEX 50 0 1056.5 ± 14.8 
Adju-Phos 
OVA 18.7 -- 1051.4 ± 49.5 
DEX -- 0 985.4 ± 9.9 
OVA+DEX 11.8 0 979.6 ± 10.5 
MF 59a 
OVA 6.4 -- 307.7 ± 22.7 
DEX -- 85 257 ± 12.3 
OVA+DEX 8.4 85 231.5 ± 12.2 
IFA 
OVA 9.3 -- 135.5 ± 5.3 
DEX -- 47.5 131.8 ± 9.1 
OVA+DEX 1.5 35.5 129.5 ± 6.1 
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Figure 1. Dexamethasone release from each adjuvant. Free or adjuvanted DEX was added to a dialysis 
unit, and DEX release was measured based on DEX in the dialysis buffer. (a) The release of DEX was 
slowest in emulsions over 120 hours; however, (b) DEX release was not significantly different between 
the samples in the first 6 hours.  Statistics are relative to free DEX ** p<0.01, ++ p<0.0001  
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Figure 2. Adjuvant-only treated dendritic cells. (a) –LPS/-OVA, (b) –LPS/+OVA, (c) +LPS/-OVA, and 
(d) +LPS/+OVA dendritic cells were cultured with bare adjuvants. Aluminum adjuvants promote 
significantly more TNF secretion after 72 hours, and emulsions maintain statistically similar or lower 
TNF concentrations compared to the control. The normalized concentration of secreted TNF is shown 
with bars corresponding to the left axis and the normalized metabolic activity is shown with purple lines 
corresponding to the right axis. Statistical significance is with respect to the media control at the 
corresponding time point: * p<0.05, ** p<0.01, + p<0.001, ++ p<0.0001 
 
 
Figure 3. Dendritic cells treated with adjuvant+ovalbumin. (a) –LPS/-OVA, (b) –LPS/+OVA, (c) +LPS/-
OVA, and (d) +LPS/+OVA dendritic cells were cultured with adjuvants+OVA. While the aluminum 
adjuvants + OVA induced high levels of TNF in non-activated conditions, the effect of the adjuvant was 
eliminated in +LPS conditions. Graphs formatted as described in Figure 2. Statistical significance is with 
respect to the ovalbumin control at the corresponding time point: * p<0.05, ** p<0.01, + p<0.001, ++ 
p<0.0001 
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Figure 4. Dendritic cells treated with adjuvant+dexamethasone. (a) –LPS/-OVA, (b) –LPS/+OVA, (c) 
+LPS/-OVA, and (d) +LPS/+OVA dendritic cells were cultured with adjuvants+DEX. DEX delivered 
with adjuvants greatly mitigated resultant TNF concentrations in –LPS DCs compared to the adjuvants 
or adjuvants+OVA.. Graphs formatted as described in Figure 2. Statistical significance is with respect to 
the dexamethasone control at the corresponding time point: * p<0.05, ** p<0.01, + p<0.001, ++ p<0.0001 
 
 
Figure 5. Dendritic cells treated with adjuvant+ovalbumin+dexamethasone. (a) –LPS/-OVA, (b) –
LPS/+OVA, (c) +LPS/-OVA, and (d) +LPS/+OVA dendritic cells were cultured with 
adjuvants+OVA+DEX. Addition of OVA to the adjuvants and DEX did not negate the anti-inflammatory 
activity of DEX, and greatly reduced the TNF levels. The normalized concentration of secreted TNF is 
shown with bars corresponding to the left axis and the normalized metabolic activity is shown with purple 
lines corresponding to the right axis. Statistical significance is with respect to the OVA+DEX control at 
the corresponding time point: * p<0.05, ** p<0.01, + p<0.001, ++ p<0.0001 
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Figure 6. –LPS/+OVA dendritic cells cultured for 120 hours with free or adjuvanted ovalbumin and 
dexamethasone. Dexamethasone, even in the presence of ovalbumin and adjuvant, can reduce the size and 
activated morphology of primed DCs. Nuclei were stained using DAPI and are shown in blue, actin was 
stained with phalloidin-AlexaFluor 568 shown in yellow. Images shown are representative of at least two 
experiments. Scale bar is 10 m. 
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Figure 7. +LPS/+OVA dendritic cells cultured for 120 hours with free or adjuvanted ovalbumin and 
dexamethasone. Treatments including MF59a with DEX best maintained an inactivated DC morphology. 
Nuclei were stained using DAPI and are shown in blue, actin was stained with phalloidin-AlexaFluor 568 
shown in yellow. Images shown are representative of at least two experiments. 
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Figure 8. Normalized metabolic activity of BMDC-splenocyte coculture. Metabolic activity of all groups 
was normalized to the untreated cells at 24 hours. ++ p<0.0001 
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Figure 9. Normalized TNFa concentration in BMDC-splenocyte coculture. -LPS/+OVA BMDCs treated 
with either MF59a+DEX or MF59a+OVA+DEX maintained significantly lower concentrations of TNFa 
in co-culture with OT-II splenocytes compared to untreated and OVA-treated samples after 48 hours. 
Concentrations were normalized to the untreated cells at 24 hours. * p<0.05, ** p<0.01, + p<0.001, ++ 
p<0.0001  
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Figure 10. Normalized cytokines from treated BMDCs cultured with splenocytes. (a) IL-2, (b) GM-CSF, 
(c) IFN, (d) IL-4, (e) IL-10. Cytokines were normalized to the untreated cells at 24 hours and the average 
metabolic activity of each treatment group at the indicated time. * p<0.05, ** p<0.01, + p<0.001, ++ 
p<0.0001  
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 Supplementary 
Figure 1. Same 
normalized TNF 
data as shown in 
Figures 2-5, but with 
all statistical 
significance 
reported.  
* p<0.05, ** p<0.01, 
+ p<0.001, ++ 
p<0.0001 
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Supplementary Figure 2. Same normalized TNF data as shown in Figures 2-5, but grouped to show 
statistical significance between different formulations of the same adjuvant. * p<0.05, ** p<0.01, + 
p<0.001, ++ p<0.0001 
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1. Conclusions  
Adjuvants have been a vital component of many successful vaccines in that they create stronger 
antigen-specific immune responses with smaller doses of purified antigen. Despite the prolific use of 
aluminum-based adjuvants and growing experience with other adjuvants, their mechanisms of action 
remain poorly understood. While aspects of their immune-stimulating effects may be attributed to 
receptor-mediated signaling, few have considered how the interaction between an adjuvant and the cell 
membrane can contribute to its mechanisms of action, or even explain discrepancies in the many proposed 
mechanisms. As reviewed in chapter 1 the physiochemical properties of many adjuvants make them 
capable of interacting with cell membranes; and in chapters 2, 3, and 4 we confirmed the organizing 
potential of adjuvant-lipid interactions and observed their potential to stimulate or diminish immune 
responses. Given the strong evidence of adjuvant-mediated lipid organization and its potential 
involvement in shaping immune responses shown here, it is evident that lipid interactions may be a 
valuable consideration while selecting or developing the physiochemical properties of an adjuvant. 
Aluminum adjuvants have been observed to cause cell damage, but they have also been 
implicated in signal activation by promoting lipid clustering via interactions with sphingomyelin and 
cholesterol. In chapter 2, the aluminum adjuvants Alhydrogel (AH) and Adju-Phos (AP) were observed to 
enhance lipid domain clustering even in a simple, monolayer model of the bulk plasma membrane 
composed of saturated dipalmitoyl-phosphatidylcholine (DPPC) and unsaturated dioleoyl-
phosphatidylcholine (DOPC). Surface pressure measurements and fluorescence microscopy images 
verified aluminum adjuvant-induced increase in lipid domain size. Additionally, adjuvant-induced lipid 
clustering differed based on the physicochemical properties of the adjuvants, especially charge and 
morphology. AH appeared to reduce monolayer compressibility and insert into the monolayer, while AP 
induced more significant changes in domain size, without compromising the integrity of the monolayer. 
The AH- and AP-mediated reorganization of domains in simple phospholipid membranes supported the 
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new mechanistic paradigm proposed by Shi and co-workers [1], and motivated further investigation in 
more complex membrane systems. 
In chapter 3, we investigated the interaction of AH and AP with membranes which included the 
major lipid components of lipid rafts, sphingomyelin (SM) and cholesterol (Ch). To model the dendritic 
cell membrane, SM and Ch were added to palmitoyl-oleoyl-phosphocholine (POPC) and palmitoyl-
oleoyl-phosphoethanolamine (POPE). Consistent with the findings of chapter 2, disparities in particle 
charge and shape continued to differentiate adjuvant-monolayer interactions. Both adjuvants stabilized 
larger condensed domains and delayed the miscibility transition of the monolayer. In fact, a miscibility 
transition was not observed in the presence of AH through the surface pressures tested. Our results 
suggested AH is present in the monolayer and promotes domain clustering by reducing line tension, while 
AP promotes domain clustering at the air-water interface. The lipid-sorting capacity of each adjuvant was 
still apparent even in the presence of highly surface active ovalbumin (OVA). In vitro, AH and AP were 
observed to enhance lipid raft clustering in dendritic cells, especially in activated dendritic cells which are 
reported to have higher levels of SM [2, 3]. Cytokine analysis of these activated cells also revealed greater 
levels of the pro-inflammatory cytokine TNF in response to bare adjuvant, but not any condition 
containing OVA. Along with increased SM content, mature dendritic cells lose their endocytic capacity 
[3-5]; therefore, the enhanced TNF concentrations induced by bare adjuvants would further support the 
hypothesis that aluminum-based adjuvants may promote pro-inflammatory signaling via enhanced 
clustering of lipid rafts.   
In chapter 4, knowledge of adjuvant-membrane interactions was used to rationally design 
immune quelling, adjuvant-based antigen-specific immunotherapies (ASIT). Given the ability of 
adjuvants to interact with antigen presenting cells, they provided a compelling vehicle to co-deliver 
antigen and immunosuppressing drug to a more limited, key population of cells which initiate and 
propagate many autoimmune diseases. Compared to the other adjuvants tested, a lab-produced analog of 
MF59 was found to carry dexamethasone (DEX) at the greatest concentration, and could more slowly 
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release DEX into medium, thus suggesting utility for co-delivering this immunosuppressant and antigens. 
In general, the addition of DEX subdued the pro-inflammatory activity of adjuvant with or without OVA 
in dendritic cells. However, the MF59 analog, whose hydrophobic properties promote non-specific 
uptake, maintained consistently low concentrations of TNFin dendritic cells at different levels of 
activationWhen treated dendritic cells were cultured with splenocytes from OT-II transgenic mice, 
formulations which included the MF59 analog and DEX improved the viability of the co-culture, and also 
maintained low concentrations of several pro-inflammatory cytokines. Therefore, adjuvants like MF59 
may be an ideal co-delivery vehicle for ASITs by reducing global concentrations of poorly soluble 
immunosuppressant drugs in the body, but promoting enhanced drug uptake to relevant immune cell 
populations.  
2. Future Work 
Although this work highlights the importance of considering adjuvant-lipid interactions in both 
immune-activating and immune-suppressing formulations, there are many aspects of this interaction that 
remain to be explored. The results presented here suggest the adjuvant-lipid behavior observed in our 
biophysical model systems may be relevant to adjuvant interactions with the plasma membrane; however, 
these models fall short of representing the true heterogeneity and complexity of the living cell membrane. 
Future studies will require more complex systems and sophisticated experimental methods to fully grasp 
and utilize the immune-regulating mechanisms provided by membrane interactions. 
The adjuvant-membrane interactions in chapters 2 and 3 were almost entirely based on 
zwitterionic lipid monolayers. Monolayers are valuable in proof-of-concept studies, but bilayers would 
provide a more accurate representation of the plasma membrane. Lipid bilayers would also offer a better 
model to investigate how adjuvant particles interact with, or traverse the plasma membrane, and therefore 
the extent of their binding, organization, and incorporation. The nature of the adjuvant-bilayer interaction 
could more qualitatively be observed in giant unilamellar vesicles which would more closely resemble the 
curvature of a cell. Giant plasma membrane vesicles (GPMVs) are harvested from the blebs of cell 
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membranes and have been shown to preserve the lipid and protein composition of a cell’s plasma 
membrane [16]. GPMVs could therefore be used to investigate adjuvant interaction with a far more 
accurate model of the surface of a cell of interest. More quantitative analysis would be possible using 
supported lipid bilayers, where lipid-adjuvant interaction could be measured and the location of the 
adjuvant visualized via atomic force microscopy (AFM), or quartz crystal microbalance with dissipation 
(QCM-D) monitoring with the inclusion of a fluorescent probe. 
 With a more rounded set of experimental methods, adjuvant interactions could also be 
investigated in different environments. Although aluminum adjuvant-induced membrane sorting was 
proposed to inhibit phagocytosis in dendritic cells [1], many have visually confirmed uptake of multiple 
adjuvants in phagocytic cells. Moreover, aluminum adjuvants in particular have been suggested to 
destabilize lysosomes, resulting in the activation of the NLRP3 inflammasome [6-10]. Therefore, it would 
be worthwhile to investigate lipid-adjuvant interactions under lysosomal conditions. The pH of the 
lysosome ranges from about 4.5 to 5.4 [11], which could not only alter the ionization state of the lipids, 
but, in the case of aluminum adjuvants, could also alter the charge of AP (point of zero charge is 
approximately at pH 5 [10]), or allow the formation of aluminum ions. The deleterious effects of free Al3+ 
on cell membranes in plants and animals have been well-documented at low pH [12], therefore studying 
aluminum adjuvants’ interaction with cell membranes at lysosomal pH could not only add another layer 
of dimension to their interaction, but could also explain how these adjuvants rupture lysosomes to activate 
the inflammasome.  
 The membrane models used in these experiments were modeled after dendritic cell membranes, 
but future studies could study lipids, or lipid mixtures representative of other cells of interest in different 
levels of activation. As the field of lipidomics grows, the lipid content of different cells is more accurately 
defined and may highlight differences between cells, and potentially different modes of interaction with 
adjuvants. Additionally, the lipid environment of an immune cell can change due to lipid metabolism 
linked to its activation. Different means of cell activation have been shown to upregulate lipids like 
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cholesterol and sphingomyelin or ceramide in the cell membrane, and in some cells activation has been 
shown to alter phosphatidylserine (PS) asymmetry, such that some PS is distributed to the outer leaflet of 
the plasma membrane [2, 3, 13]. Anionic phospholipids such as PS and phosphatidylinositol, especially 
phosphatidylinositol (4,5) bisphosphate (PIP2), are known to play major roles in signaling related to 
immune silencing or activation from the cytosolic leaflet of the membrane. PS and PIP2 also cluster to 
regulate signaling, and the domains can be linked to lipid rafts on the outer leaflet [13-15]. Ergo, adjuvants 
which sort raft lipids may also have a reciprocal organizational effect on PS or PIP2 on the cytoplasmic 
face of the plasma membrane, and could also participate in lipid-mediated signaling.  
Likewise, further in vitro or in vivo studies could be conducted to evaluate the metabolic products 
of different adjuvants. As reviewed in chapter 1, metabolism of emulsion surfactants results in excess 
accumulation of neutral lipids, which can cause inflammation and apoptotic signaling [17]. Although 
emulsions could be formulated to produce metabolites to tune inflammatory signaling, emulsions could 
also incorporate components which promote anti-inflammatory pathways. For instance, polyunsaturated 
fatty acids (PUFAs) have been found to either enhance or disrupt immune activation depending on the 
chain length of the fatty acid. Several PUFAs, including omega-3 PUFAs, have been observed to suppress 
the activity of T cells, neutrophils, monocytes, and macrophages in vitro and in vivo by incorporating into 
the sn-2 position of phospholipids and altering lipid packing, making the membrane more fluid and 
disrupting immune signaling [13, 18, 19]. Abnormal expression or packing of lipid raft lipids has been 
implicated in several autoimmune and inflammatory diseases such as systemic lupus erythematosus, 
multiple sclerosis, and inflammatory bowel diseases [13, 20, 21], thus, compounds which alter effective 
packing of these lipids could be an effective therapy. 
Alternatively, emulsions composed of different immunomodulating compounds could also be 
investigated to expand on the MF59 analog-based ASIT formulation investigated in chapter 4. For 
instance, tocopherols, like vitamin E, are oils with inherent antioxidant and anti-inflammatory properties 
which have been successfully emulsified using other tocopherol derivatives [22]. These emulsions would 
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retain the enhanced non-specific, hydrophobic uptake by cells, would likely still be able to solubilize and 
slowly release hydrophobic immunosuppressive drugs, and would have the added benefit of providing 
additional anti-inflammatory capacity. In vivo experiments of any emulsion-based ASIT will be necessary 
to confirm if (1) the reduction in anti-inflammatory signaling observed in vitro is maintained, (2) the 
immune suppression is antigen-specific, and (3) the suppression is maintained following challenge with 
the antigen. It will also be valuable to identify the key populations with which these formulations interact 
to more specifically study how they manipulate the immune response and affect indicators of immune 
activation, such as expression of cytokines, co-stimulatory surface proteins, and T cell proliferation. 
Development of tocopherol-based emulsions is ongoing in our lab with promising preliminary results in 
an animal model of multiple sclerosis.  Other iterations of emulsion-based ASITs could include different 
poorly-soluble immunosuppressant drugs, such as rapamycin, and other antigens associated with 
autoimmunity. Especially as the field grows closer to being able to finely observe nanoscale lipid motility 
and metabolism in individual cells in real time, adjuvant-lipid interactions will continue to be a valuable 
consideration in creating novel and creative vehicles to tune pro- and anti-inflammatory ASITs. 
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